var title_f20_58_21408="Bladder severe hydronephros";
var content_f20_58_21408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thickened bladder wall and key hole sign with severe hydronephrosis in a 30 4/7 week old fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    BL:Bladder, RT:Right kidney, LT:Left kidney",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21408=[""].join("\n");
var outline_f20_58_21408=null;
var title_f20_58_21409="Myocardial bridging of the LAD";
var content_f20_58_21409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Myocardial bridging of the LAD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left coronary angiogram is shown in diastole (left frame) and systole (right frame). There is marked systolic narrowing of the proximal left anterior descending artery (arrow) consistent with myocardial bridging.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21409=[""].join("\n");
var outline_f20_58_21409=null;
var title_f20_58_21410="Tube patency";
var content_f20_58_21410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Tympanostomy tube patency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 488px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proper function of a tympanostomy tube is assured if it is seen to span the eardrum, its lumen is unobstructed, and no middle ear effusion is present. Panel A above depicts a tube that is in place and patent. Panel B depicts a tube that is in place, but occluded. Panel C depicts a tube that is in place and patent, but appears to have extruded.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G, Rosenfeld RM. Care of the child with tympanostomy tubes. A visual guide for the pediatrician. Pediatrics 1994; 93:924. Copyright &copy; 1994 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21410=[""].join("\n");
var outline_f20_58_21410=null;
var title_f20_58_21411="Female pattern hair loss 1";
var content_f20_58_21411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked reduction in terminal hair density is present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21411=[""].join("\n");
var outline_f20_58_21411=null;
var title_f20_58_21412="Calcium phosphate, tribasic: Drug information";
var content_f20_58_21412=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium phosphate, tribasic: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/7/20596?source=see_link\">",
"    see \"Calcium phosphate, tribasic: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/24/13701?source=see_link\">",
"    see \"Calcium phosphate, tribasic: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Posture&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, Females/Males: RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     19-50 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;51 years, females: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     51-70 years, males: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dietary supplement:",
"     </b>",
"     Oral: 2 tablets daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/24/13701?source=see_link\">",
"      see \"Calcium phosphate, tribasic: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1-6 months: Adequate intake: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     7-12 months: Adequate intake: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1-3 years: RDA: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     4-8 years: RDA: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     9-18 years: RDA: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Female: Pregnancy/Lactating: RDA: Requirements are the same as in non-pregnant or non-lactating females",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     RDA: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males &le;70 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males &gt;70 years: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dietary supplement:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Posture&reg;: Calcium 600 mg and phosphorus 280 mg [as tricalcium phosphate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Constipation, dry mouth, hypercalcemia, hypophosphatemia, milk-alkali syndrome, nausea",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Constipation, bloating, and gas are common with calcium supplements (especially carbonate salt).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Achlorhydria: Calcium absorption is impaired in achlorhydria; common in elderly, use an alternate salt (eg, citrate) and administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroid disease: Hypercalcemia and hypercalciuria are most likely to occur in hypoparathyroid patients receiving high doses of vitamin D.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minerals/other oral drugs: Calcium administration interferes with absorption of some minerals and drugs; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin D: It is recommended to concomitantly administer vitamin D for optimal calcium absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Taking calcium (&le;500 mg) with food improves absorption.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, administration of an iron-containing multivitamin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F144750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13333872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13333873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F12875001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum calcium: 8.5-10.5 mg/dL. Monitor plasma calcium levels if using calcium salts as electrolyte supplements for deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corrected total calcium = total serum calcium + 0.8 (4.0 - measured serum albumin)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As dietary supplement, used to prevent or treat negative calcium balance; in osteoporosis, it helps to prevent or decrease the rate of bone loss. The calcium in calcium salts moderates nerve and muscle performance and allows normal cardiac function.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8832 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21412=[""].join("\n");
var outline_f20_58_21412=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144763\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144754\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144760\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144755\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144745\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144733\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144746\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144762\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144737\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298943\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144741\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144750\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333872\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333873\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12875001\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144736\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/7/20596?source=related_link\">",
"      Calcium phosphate, tribasic: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/24/13701?source=related_link\">",
"      Calcium phosphate, tribasic: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_58_21413="Noninflammatory lesions PI";
var content_f20_58_21413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Noninflammatory lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The combination of open and closed comedones, as seen here, is most common in younger patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21413=[""].join("\n");
var outline_f20_58_21413=null;
var title_f20_58_21414="Use of home cardiorespiratory monitors in infants";
var content_f20_58_21414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of home cardiorespiratory monitors in infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21414/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21414/contributors\">",
"     Michael J Corwin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21414/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21414/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21414/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21414/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21414/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/58/21414/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Home cardiorespiratory (CR) monitors have been available for approximately 30 years, and were originally intended to prevent sudden infant death syndrome (SIDS) in at-risk infants. Since then, it has become clear that the CR monitor is not an effective tool to prevent SIDS.",
"   </p>",
"   <p>",
"    Nonetheless, there is some justification for the use of CR monitors in selected infants with other underlying disorders. Selection of infants for monitoring depends upon the infant's underlying problem and the capabilities of the monitor. In many cases, the primary utility of the monitor is diagnostic (ie, to distinguish genuine from false CR events and document the nature and frequency of CR events) rather than therapeutic (ie, to provide an alarm that allows intervention to terminate events).",
"   </p>",
"   <p>",
"    The appropriate use of CR monitors for specific disorders, the capabilities and limitations of the devices, and the management of infants with CR monitors will be reviewed here. The pathophysiology, evaluation, and other approaches to managing the disorders for which CR monitoring is sometimes considered are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=see_link\">",
"     \"Apparent life-threatening event in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link\">",
"     \"Management of apnea of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTROVERSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of home cardiorespiratory (CR) monitors has become increasingly controversial. In a 1987 NIH Consensus Statement on Infantile Apnea and Home Monitoring, home CR monitoring was recommended for infants thought to be at-risk for sudden infant death syndrome (SIDS). At that time, at-risk infants were thought to include premature infants with episodic apnea or bradycardia, infants who had experienced one or more severe apparent life threatening events (ALTE), and siblings of two or more SIDS victims. However, the authors of the statement were also careful to point out that \"the effectiveness of home monitoring in reducing infant mortality and morbidity is not yet established.\"",
"   </p>",
"   <p>",
"    Since the publication of this document, advances in the understanding of the pathophysiology of these disorders, outcomes of clinical trials, and clinical experience have substantially narrowed the indications for CR monitor use. One must also consider the high costs of continuous monitoring, which include the device, training and respite of caretakers, and analysis of recorded events. In addition, concerns have been raised that the use of CR monitors might distract from other established preventive measures (eg, safe sleeping environment for prevention of SIDS), have adverse effects on the parents' quality of life, and present difficulties in determining an end point for monitoring.",
"   </p>",
"   <p>",
"    A major problem in assessing the role of CR monitors to prevent infant death is that clinical efficacy cannot be established. Randomized controlled trials are impractical because death is a rare event in these infants, and because families are unlikely to consent to randomization.",
"   </p>",
"   <p>",
"    The rationale for or against the use of CR monitoring for specific disorders is discussed below. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Monitoring decisions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEVICES AND CAPABILITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard home cardiorespiratory (CR) devices detect when the heart rate falls below or above a preset range or when there is no chest wall movement for a preset length of time. Most currently used monitors also record waveforms during events (documented monitoring), which can facilitate diagnosis and decisions about when to stop monitoring. Oxygen saturation measurements can be included on some monitors if specifically requested.",
"   </p>",
"   <p>",
"    These devices directly measure central apnea by the lack of respiratory effort. They do NOT detect obstructive apnea in the absence of bradycardia.",
"   </p>",
"   <p>",
"    Thus, the clinical utility of the monitor depends upon the pathophysiology of the underlying disorder. It will be more useful for infants at risk for central apnea or bradycardia (eg, apnea of prematurity) than for disorders in which apnea or bradycardia are late consequences of hypoxemia. If oxygen saturation measurements are included, the device may provide somewhat earlier recognition of events in infants with primary respiratory disease (eg, those with a tracheostomy or neuromuscular disease) provided that caretakers can respond in time to reverse the problem [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MONITORING DECISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision as to whether or not cardiorespiratory (CR) monitoring should be considered in an individual infant varies with the underlying disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Asymptomatic infants with risk factors for sudden infant death syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden infant death syndrome (SIDS) is defined as the sudden death of an infant younger than one year of age that remains unexplained despite a thorough case investigation, including autopsy, examination of the death scene, and review of the clinical history [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/2\">",
"     2",
"    </a>",
"    ]. Although prematurity is one of several risk factors for SIDS, the mechanism and timing of SIDS are distinct from those of apnea of prematurity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the 1970s, it was proposed that prolonged central apnea was an early and, perhaps, primary event in the pathogenesis of SIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/3\">",
"     3",
"    </a>",
"    ]. This \"apnea hypothesis\" was based on observations of recurrent brief apneic episodes during sleep in several infants, which resolved as the infants matured. Infants with these features were thought to be at risk for SIDS, and CR monitoring was proposed in an effort to prevent death.",
"   </p>",
"   <p>",
"    Since then, several important advances have indicated that apnea is not an initial event in the pathogenesis of SIDS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several infants have died with home CR monitoring devices in place, and a body of literature has emerged presenting the data from so-called \"death tracings\" [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. The data obtained from death tracings suggests that bradycardia occurs first and is followed by terminal apnea. It is hypothesized that hypoxia precedes the recorded bradycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Academy of Pediatrics launched the \"Back to Sleep\" campaign advocating supine sleeping in 1992 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/9\">",
"       9",
"      </a>",
"      ]. Since that time, the SIDS rates in the United States have decreased by over 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/10-12\">",
"       10-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increasing attention has been focused on the issue of child abuse and infanticide masquerading as recurrent apparent life-threatening events (ALTE) or SIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/13-16\">",
"       13-16",
"      </a>",
"      ]. A widely publicized case of five successive deaths in a family in New York resulted in greater recognition of this entity, especially in families with more than one occurrence among siblings [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epidemiologic studies and two decades of clinical experience have failed to show an effect of CR monitors in reducing the incidence of SIDS in infants presumed to be at risk [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies using plethysmographic monitors capable of detecting both central and obstructive apnea in infants presumed at risk for SIDS displayed a high frequency of obstructed breathing, which would not be detected by conventional monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there are currently no data to support the therapeutic use of cardiorespiratory monitoring as a means of reducing the risk for SIDS in asymptomatic infants, regardless of SIDS risk factors that may be present (e.g. prior sibling SIDS death, or prematurity). However, the physiologic parameters recorded by current monitors may have some diagnostic value, by defining the types of physiologic abnormalities occurring in some subgroups of infants, including symptomatic preterm infants, infants with apparent life threatening events, and infants with other underlying disorders, as discussed below.",
"   </p>",
"   <p>",
"    Counseling parents of asymptomatic infants with risk factors for SIDS who request a home monitor may be challenging.&nbsp;We suggest that the clinician engage parents in a focused conversation that describes the potential negative consequences of using a home monitor and makes it clear that they should not consider a monitor to be a SIDS prevention strategy.&nbsp;However, we also suggest acknowledging that parents appropriately feel the need to watch their baby closely and that all parents have to decide how best to watch and check on their baby. In rare cases, where it is believed that the parents cannot cope using conventional strategies to watch their baby (ie, having the baby sleep in the parents&rsquo; room, periodic entering the sleep room, or use of standard baby room listening devices), it may be reasonable to support the parents&rsquo; desire to watch their baby with a home cardiorespiratory monitor.&nbsp;However, in such cases, it is critical to ensure that the parents have a clear understanding of the reason for using the monitor and the plan for when it should be discontinued (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Counseling of parents'",
"    </a>",
"    below). Finally, it is important to emphasize the need for the parents to follow recommended infant care practices related to reducing SIDS risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link&amp;anchor=H29#H29\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preterm infants with persistent symptoms related to apnea of prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apnea of prematurity is defined as the sudden cessation of breathing that lasts for at least 20 seconds or is accompanied by bradycardia or oxygen saturation in an infant younger than 37 weeks postmenstrual age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link\">",
"     \"Management of apnea of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most apneic events are central (ie, cessation of respiratory effort), and the disorder is thought to be caused by immaturity of respiratory control mechanisms. The breathing pattern matures with increasing postmenstrual age. Nonetheless, preterm infants continue to have more episodes of prolonged apnea than infants born at term until about 43 weeks postmenstrual age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Premature infants with persistent apnea of prematurity but who are otherwise ready for hospital discharge are candidates for home cardiorespiratory monitoring. Implementation of monitoring requires counseling and training of the caretakers, follow-up and review of events by a professional, and determination of an end point for monitoring. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Implementation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infants with apparent life-threatening events",
"    </span>",
"    &nbsp;&mdash;&nbsp;An apparent life-threatening event (ALTE) is an acute, unexpected change in an infant's breathing behavior that was frightening to the caretaker, and is characterized by some combination of apnea, color change, change in muscle tone, choking, or gagging. Infants experiencing ALTEs represent a heterogeneous group of patients of varying ages with diverse pathophysiology. Although a relationship between ALTEs and SIDS was initially suggested, studies during the past two decades have failed to confirm a causal relationship. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=see_link&amp;anchor=H3#H3\">",
"     \"Apparent life-threatening event in infants\", section on 'Lack of causal relationship between ALTE and SIDS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A specific cause for the ALTE can be identified in over one-half of patients after a careful history, physical examination, and appropriate laboratory evaluation. In most of these cases, the cause will be identified during the hospital evaluation, and home CR monitoring does not have additional diagnostic value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=see_link\">",
"     \"Apparent life-threatening event in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision for home monitor observation should be made on a case-by-case basis, depending upon the presumed cause of the ALTE after a careful investigation, the estimated risk of recurrence, and after considering with the family the potential benefits, uncertainties, and stresses involved. In general, CR monitors would be less helpful for infants with presumed obstructive pathophysiology than for those with central apnea. In some cases, the potential value of the monitor lies in its ability to record physiologic data that may provide reassurance that clinically important events are not occurring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with underlying diseases predisposing to respiratory failure, home CR monitoring may facilitate rapid recognition of central apnea, airway obstruction, respiratory failure, interruption of supplemental oxygen supply, or failure of mechanical respiratory support. Thus, infants with the following conditions are candidates for monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tracheostomy or airway abnormalities (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neurologic or metabolic disorders affecting respiratory control",
"     </li>",
"     <li>",
"      Chronic lung disease (eg, bronchopulmonary dysplasia), especially those requiring supplemental oxygen, positive airway pressure, or mechanical ventilatory support (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15753?source=see_link\">",
"       \"Management of bronchopulmonary dysplasia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some infants, oxygen saturation monitoring alone, or in conjunction with a CR device may provide more useful diagnostic information than a CR monitor alone. None of the currently available home CR monitors reliably detect obstructive apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMPLEMENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Counseling of parents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Families must be informed of the purpose of the monitor and what it can and cannot do. It is a tool to alert them to check the baby when an alarm is triggered either by the baby's heart rate falling below a preset limit or by the monitor's not detecting chest wall movement for a preset number of seconds. Parents must know that the monitor cannot guarantee the safety of the infant and that infants have died while being monitored.",
"     </li>",
"     <li>",
"      Regardless of the indication for monitoring, caretakers should be counseled regarding sudden infant death syndrome (SIDS) risk reduction, especially with regard to infant sleep position, crib safety factors, avoidance of exposure to tobacco smoke, and the importance of regular medical check-ups.",
"     </li>",
"     <li>",
"      Families should be aware of the stresses of monitoring. As an example, some parents feel they cannot leave the infant, and child care can be difficult to find. False alarms can cause unnecessary sleep disruption.",
"     </li>",
"     <li>",
"      Families should be told how long to expect the baby to be monitored and what criteria will be used to discontinue monitoring. Factors to consider are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The expected course of the disorder for which the infant is being monitored (eg, apnea of prematurity tends to resolve by 43 weeks postmenstrual age)",
"     </li>",
"     <li>",
"      The risk of SIDS is very low after six months of age",
"     </li>",
"     <li>",
"      The risk of becoming entangled in lead wires is increased after infants are able to roll over and sit up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Professional support",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caretakers must be taught how to perform cardiopulmonary resuscitation and other emergency responses to an alarm.",
"     </li>",
"     <li>",
"      Caretakers must have access at all times to technical support in case of problems with monitor function, and to professional support to answer questions which may arise regarding the infant's status.",
"     </li>",
"     <li>",
"      The recorded monitor data should be downloaded on a monthly basis. This should be reviewed by a professional with expertise in interpreting waveforms who can distinguish between true and false events. Clinical judgment must be used to determine whether recorded apneas or bradycardias are significant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Monitor settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitor settings should be appropriate for the infant's age. Incorrect settings can result in frequent false alarms and can fill up the monitor's memory by recording large numbers of \"events.\"",
"   </p>",
"   <p>",
"    Suggested settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apnea record &ndash; 15 sec",
"     </li>",
"     <li>",
"      Apnea alarm &ndash; 20 sec",
"     </li>",
"     <li>",
"      Tachycardia &ndash; 225 bpm",
"     </li>",
"     <li>",
"      Bradycardia limits vary by age and should be lowered as the infant grows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Up to 44 weeks postmenstrual age &ndash; 80 bpm",
"     </li>",
"     <li>",
"      44 to 51 weeks postmenstrual age &ndash; 70 bpm",
"     </li>",
"     <li>",
"      Over 52 weeks postmenstrual age &ndash; 60 bpm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    False alarms are very common, and their frequency is determined by factors including the quality of transducer placement, the level of infant activity, and the appropriateness of the alarm threshold settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     End point of monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The end point of monitoring varies with the indication for monitoring. In general, six to eight weeks of normal downloads and no clinical events is considered sufficient. Parental readiness to discontinue monitoring is also a factor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants monitored because of apnea of prematurity, monitoring can be discontinued if no true events have been detected on downloads and no important clinical events have occurred in several weeks, and if the infant is older than 43 weeks postmenstrual age [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/20\">",
"       20",
"      </a>",
"      ]. Apnea of prematurity may persist longer in infants born very prematurely [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21414/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For infants monitored because of underlying respiratory disease or anatomic airway abnormalities, the decision to continue monitoring depends primarily upon the frequency and severity of the events that trigger alarms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indications for cardiorespiratory (CR) monitor use have changed substantially during the past decade because of advances in the understanding of the pathophysiology of disorders associated with CR events during infancy, outcomes of clinical studies, and clinical experience. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Controversy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard home CR monitors detect heart rate and chest wall movement; oxygen saturation measurements can be monitored if specifically requested. The devices directly measure central apnea by the lack of respiratory effort. They do NOT detect obstructive apnea in the absence of bradycardia or a drop in oxygen saturation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Devices and capabilities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Premature infants with persistent apnea of prematurity but who are otherwise ready for hospital discharge are candidates for home CR monitoring. The decision of whether to use a monitor depends on assessment of risks and benefits for the individual infant. Monitoring can generally be discontinued by 43 weeks postmenstrual age. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Preterm infants with persistent symptoms related to apnea of prematurity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'End point of monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central apnea is not necessarily an initial event in the pathogenesis of sudden infant death syndrome (SIDS). There is no evidence that SIDS can be prevented by CR monitoring of asymptomatic infants, whether or not SIDS risk factors are present (eg, prior sibling SIDS death, or prematurity). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Asymptomatic infants with risk factors for sudden infant death syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Home CR monitoring may facilitate rapid recognition of an acute respiratory or cardiac problem in infants with underlying diseases including tracheostomy or airway abnormalities, neurologic or metabolic disorders affecting respiratory control, or chronic lung disease. For many of these infants, inclusion of oxygen saturation measurements with the CR device may allow for earlier recognition of events. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If CR monitoring is recommended, implementation requires counseling and training of the caretakers, professional oversight to analyze recordings and clinical events and determine an appropriate end point for monitoring. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Implementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/1\">",
"      Hunt CE, Corwin MJ, Lister G, et al. Precursors of cardiorespiratory events in infants detected by home memory monitor. Pediatr Pulmonol 2008; 43:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/2\">",
"      Willinger M, James LS, Catz C. Defining the sudden infant death syndrome (SIDS): deliberations of an expert panel convened by the National Institute of Child Health and Human Development. Pediatr Pathol 1991; 11:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/3\">",
"      Steinschneider A. Prolonged apnea and the sudden infant death syndrome: clinical and laboratory observations. Pediatrics 1972; 50:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/4\">",
"      Kelly DH, Pathak A, Meny R. Sudden severe bradycardia in infancy. Pediatr Pulmonol 1991; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/5\">",
"      Meny RG, Carroll JL, Carbone MT, Kelly DH. Cardiorespiratory recordings from infants dying suddenly and unexpectedly at home. Pediatrics 1994; 93:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/6\">",
"      Poets CF, Meny RG, Chobanian MR, Bonofiglo RE. Gasping and other cardiorespiratory patterns during sudden infant deaths. Pediatr Res 1999; 45:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/7\">",
"      Poets CF, Samuels MP, Noyes JP, et al. Home event recordings of oxygenation, breathing movements, and heart rate and rhythm in infants with recurrent life-threatening events. J Pediatr 1993; 123:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/8\">",
"      Poets CF. Assessing oxygenation in healthy infants. J Pediatr 1999; 135:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/9\">",
"      American Academy of Pediatrics AAP Task Force on Infant Positioning and SIDS: Positioning and SIDS. Pediatrics 1992; 89:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/10\">",
"      Positioning and sudden infant death syndrome (SIDS): update. American Academy of Pediatrics Task Force on Infant Positioning and SIDS. Pediatrics 1996; 98:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/11\">",
"      Kochanek KD, Kirmeyer SE, Martin JA, et al. Annual summary of vital statistics: 2009. Pediatrics 2012; 129:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/12\">",
"      Changing concepts of sudden infant death syndrome: implications for infant sleeping environment and sleep position. American Academy of Pediatrics. Task Force on Infant Sleep Position and Sudden Infant Death Syndrome. Pediatrics 2000; 105:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/13\">",
"      Reece RM. Fatal child abuse and sudden infant death syndrome: a critical diagnostic decision. Pediatrics 1993; 91:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/14\">",
"      Distinguishing sudden infant death syndrome from child abuse fatalities. Committee on Child Abuse and Neglect. American Academy of Pediatrics. Pediatrics 1994; 94:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/15\">",
"      Southall DP, Plunkett MC, Banks MW, et al. Covert video recordings of life-threatening child abuse: lessons for child protection. Pediatrics 1997; 100:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/16\">",
"      Kairys SW, Alexander RC, Block RW, et al. American Academy of Pediatrics. Committee on Child Abuse and Neglect and Committee on Community Health Services. Investigation and review of unexpected infant and child deaths. Pediatrics 1999; 104:1158.",
"     </a>",
"    </li>",
"    <li>",
"     Firstman R, Talan J. The Death of Innocents, Bantam Books, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/18\">",
"      Ward SL, Keens TG, Chan LS, et al. Sudden infant death syndrome in infants evaluated by apnea programs in California. Pediatrics 1986; 77:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/19\">",
"      MacKay M, Abreu e Silva FA, MacFadyen UM, et al. Home monitoring for central apnoea. Arch Dis Child 1984; 59:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/20\">",
"      Ramanathan R, Corwin MJ, Hunt CE, et al. Cardiorespiratory events recorded on home monitors: Comparison of healthy infants with those at increased risk for SIDS. JAMA 2001; 285:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/21\">",
"      National Institutes of Health Consensus Development Conference on Infantile Apnea and Home Monitoring, Sept 29 to Oct 1, 1986. Pediatrics 1987; 79:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/22\">",
"      Hunt CE, Corwin MJ, Lister G, et al. Longitudinal assessment of hemoglobin oxygen saturation in healthy infants during the first 6 months of age. Collaborative Home Infant Monitoring Evaluation (CHIME) Study Group. J Pediatr 1999; 135:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/23\">",
"      Samuels MP, Poets CF, Southall DP. Abnormal hypoxemia after life-threatening events in infants born before term. J Pediatr 1994; 125:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21414/abstract/24\">",
"      Naulaers G, Daniels H, Allegaert K, et al. Cardiorespiratory events recorded on home monitors: the effect of prematurity on later serious events. Acta Paediatr 2007; 96:195.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6349 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21414=[""].join("\n");
var outline_f20_58_21414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTROVERSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEVICES AND CAPABILITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MONITORING DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Asymptomatic infants with risk factors for sudden infant death syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preterm infants with persistent symptoms related to apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infants with apparent life-threatening events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Counseling of parents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Professional support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Monitor settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      End point of monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=related_link\">",
"      Apparent life-threatening event in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15753?source=related_link\">",
"      Management of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_58_21415="Emery-Dreifuss muscular dystrophy";
var content_f20_58_21415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emery-Dreifuss muscular dystrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21415/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21415/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21415/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21415/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21415/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21415/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/58/21415/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in a number of genes required for normal muscle function. Some of the genes responsible for these conditions have been identified. Muscle weakness is the primary symptom.",
"   </p>",
"   <p>",
"    Emery-Dreifuss muscular dystrophy (EDMD), also known as humeroperoneal muscular dystrophy, can be inherited as an X-linked recessive, autosomal dominant, or autosomal recessive disorder.",
"   </p>",
"   <p>",
"    The pathogenesis, genetics, and clinical characteristics of EDMD are discussed here. Other muscular dystrophies are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=see_link\">",
"     \"Facioscapulohumeral muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=see_link\">",
"     \"Limb-girdle muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link\">",
"     \"Oculopharyngeal, distal, and congenital muscular dystrophies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inherited forms of Emery-Dreifuss muscular dystrophy (EDMD) have similar symptoms, which usually begin in the first or second decade of life. However, adult onset with slow progression has been noted as well.",
"   </p>",
"   <p>",
"    The major features of EDMD are early contractures, slowly progressive humeroperoneal muscle",
"    <span class=\"nowrap\">",
"     weakness/wasting,",
"    </span>",
"    and cardiac disease with conduction defects and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/1\">",
"     1",
"    </a>",
"    ]. The disease exhibits significant inter- and intrafamilial variability with regard to age at onset, severity, and progression of the major manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contractures at the elbows are noted early and are commonly the first manifestations of EDMD. Contractures of the posterior aspect of the neck, the entire spine, and the Achilles tendons also occur. Achilles tendon contractures are frequently associated with toe walking. Severe spine and leg contractures may lead to loss of ambulation.",
"     </li>",
"     <li>",
"      Muscle weakness and wasting has a humeroperoneal distribution; it frequently begins in the arms, involving both the biceps and triceps, with relative preservation of the deltoid muscles. Subsequently, distal leg weakness with atrophy of the peroneal muscles is noted. In some cases, mild facial weakness may also be observed. The myopathy tends to be slowly progressive during the first three decades of life, but more rapid thereafter.",
"     </li>",
"     <li>",
"      A dilated cardiomyopathy may be seen in most patients with EDMD. It is typically associated with atrioventricular conduction abnormalities. Other common findings include atrial paralysis, atrial fibrillation, and atrial flutter. Symptoms of hypoperfusion (syncope or near syncope) often result from infranodal or atrioventricular conduction block with the development of slow junctional rhythms that often require pacemaker insertion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. Sudden death can occur and may develop in patients not previously diagnosed because of mild or no skeletal myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;EDMD is associated with abnormalities in serum creatine kinase (CK), electrocardiogram (ECG), electromyogram (EMG), muscle imaging, and muscle biopsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A modest elevation of serum CK concentration, rarely higher than a few hundred",
"      <span class=\"nowrap\">",
"       units/L,",
"      </span>",
"      is typical. Increases up to 20 times the upper limit of normal sometimes occur, but may be seen more often in the early stages of the disease.",
"     </li>",
"     <li>",
"      The ECG may show varying degrees of atrioventricular block, small T waves, and atrial arrhythmias.",
"     </li>",
"     <li>",
"      The EMG usually displays myopathic features and may also reveal evidence of denervation.",
"     </li>",
"     <li>",
"      The muscle biopsy typically shows mild myopathic changes characterized by internal nuclei, variation in fiber size, focal connective tissue proliferation, and occasional necrotic fibers (",
"      <a class=\"graphic graphic_algorithm graphicRef52444 \" href=\"UTD.htm?21/21/21841\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Muscle immunohistochemistry will reveal absence of emerin in approximately 95 percent of patients with X-linked EDMD [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/5\">",
"       5",
"      </a>",
"      ]. Emerin can also be detected by immunofluorescence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      western blot testing in muscle and other tissues including skin, exfoliative buccal cells, lymphocytes, and lymphoblastoid cell lines [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with LMNA gene mutations, leg muscle imaging reveals changes in the soleus and medial gastrocnemius muscles. However, the pattern is similar in essentially asymptomatic and severely symptomatic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Molecular genetic testing, if positive, will confirm the diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;EDMD is a genetically heterogenous disorder with X-linked recessive, autosomal dominant, and autosomal recessive forms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/9\">",
"     9",
"    </a>",
"    ]. Several forms are considered nuclear envelopathies because they are associated with mutations in genes encoding nuclear membrane proteins, including the EMD gene that encodes for emerin, the LMNA gene that encodes for lamin",
"    <span class=\"nowrap\">",
"     A/C,",
"    </span>",
"    and the SYNE1 and SYNE2 genes that encode for nesprin 1 and nesprin 2, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     X-linked forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The X-linked forms of the disorder are EDMD1 and EDMD6:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EMD gene on Xq28 (EDMD1) encodes emerin, a protein that is localized to the nuclear membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/11-14\">",
"       11-14",
"      </a>",
"      ]. Most mutations are null mutations resulting in complete loss of emerin expression in muscle. Missense mutations are associated with decreased or even normal amounts of emerin and result in a milder phenotype.",
"     </li>",
"     <li>",
"      The FHL1 gene on Xq26.3 (EDMD6) encodes the four-and-a-half LIM domains protein 1 and is associated with an X-linked EDMD phenotype and hypertrophic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Mutations in the FHL1 gene result in delayed myotube formation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nomenclature and classification of FHL1-linked",
"    <span class=\"nowrap\">",
"     myopathies/muscular",
"    </span>",
"    dystrophies is still evolving. In addition to EDMD6, FHL1 mutations have also been identified in patients with X-linked myopathy with postural muscle atrophy, X-linked dominant scapuloperoneal myopathy, X-linked reducing body myopathy with early childhood onset, and myofibrillar myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Common features of FHL1 disorders include joint contractures, spinal rigidity, and cardiac involvement. Reducing body aggregates in muscle biopsies are a characteristic feature of reducing body myopathy and scapuloperoneal myopathy. In contrast, muscle biopsies of patients with EDMD6 do not show reducing bodies, but the expression of FHL1A protein is moderately to severely decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autosomal dominant and recessive forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both an autosomal dominant (EDMD2) and a rare autosomal recessive (EDMD3) form are linked to mutations of the LMNA gene on chromosome 1q21.2 that encodes for lamin",
"    <span class=\"nowrap\">",
"     A/C,",
"    </span>",
"    a protein found in the nuclear membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other EDMD-like phenotypes with autosomal dominant inheritance are linked to mutations of SYNE1 (EDMD4) and SYNE2 (EDMD5), both of which encode for nuclear membrane proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. However, the number of reported cases is small and thus the muscle phenotype remains to be defined.",
"   </p>",
"   <p>",
"    Mutations in the TMEM43 gene, which encodes another nuclear membrane protein, are also associated with an EDMD-like phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/23\">",
"     23",
"    </a>",
"    ]. Such mutations were found in 2 of 41 patients with EDMD-related myopathy. As with SYNE1 and SYNE2, additional data are needed to further delineate the phenotype of TMEM43-related myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laminopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The correlation between LMNA genotype and phenotype has been poor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition to EDMD, a number of laminopathies (ie, disorders caused by LMNA gene mutations) have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limb-girdle muscular dystrophy with atrioventricular conduction defects (LGMD1B) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/26\">",
"       26",
"      </a>",
"      ]. This association suggests that EDMD2 and LGMD1B are allelic disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/26\">",
"       26",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=see_link\">",
"       \"Limb-girdle muscular dystrophy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autosomal dominant dilated cardiomyopathy with conduction defects (CMD1A or DCM-CD) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autosomal dominant dilated cardiomyopathy with apical left ventricular aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autosomal dominant quadriceps myopathy with dilated cardiomyopathy and associated conduction defects [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A relatively severe form of congenital muscular dystrophy classified as LMNA-related congenital muscular dystrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Charcot-Marie-Tooth type 2B1 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autosomal dominant Dunnigan type familial partial lipodystrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mandibuloacral dysplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hutchinson-Gilford progeria syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several reports have found patients harboring mutations in both EDMD and LMNA genes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The clinical presentations included severe EDMD, a combination of Charcot-Marie-Tooth type 2 and EDMD, and isolated cardiomyopathy.",
"   </p>",
"   <p>",
"    Mutations in both emerin and desmin genes were found in a patient with cardioskeletal myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases with typical clinical features of EDMD and a supportive family history, genetic testing may avoid the need for electromyography and muscle biopsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical laboratory DNA testing (sequence analysis) of the emerin (EMD) gene is available for the X-linked form of EDMD and detects EMD mutations in &gt;99 percent of patients with an X-linked inheritance pattern",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with no emerin expression in muscle biopsy tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/24,40\">",
"       24,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with autosomal dominant EDMD, gene sequence analysis or mutation scanning will detect LMNA sequence variants in about 45 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/24\">",
"       24",
"      </a>",
"      ]. Autosomal recessive EDMD has been reported in only a few individuals. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Autosomal dominant and recessive forms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the family history is positive, it may help in making the diagnosis of a particular EDMD subtype (eg, X-linked versus autosomal dominant).",
"   </p>",
"   <p>",
"    In sporadic or atypical cases, the presence of myopathic changes on electromyography and muscle biopsy is supportive of EDMD. Emerin is absent from nuclei of skeletal muscle myocytes in X-linked EDMD. Thus, the diagnosis may be based upon immunohistologic examination of a muscle biopsy with confirmatory genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further genetic testing for mutations in LMNA, FHL1, SYNE1 or SYNE2 genes is appropriate if nuclear staining for emerin is detectable (",
"    <a class=\"graphic graphic_algorithm graphicRef52444 \" href=\"UTD.htm?21/21/21841\">",
"     algorithm 1",
"    </a>",
"    ). However, in a male with a mild phenotype",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an X-linked pattern of inheritance, sequence analysis of the EMD gene should be performed (to exclude a missense mutation) before proceeding with genetic testing for other genes. Immunodetection of lamins",
"    <span class=\"nowrap\">",
"     A/C",
"    </span>",
"    is not a reliable diagnostic test because their expression is usually normal in patients with EDMD2 and EDMD3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than the different inherited muscular dystrophies and myopathies, the differential diagnosis of EDMD includes the rigid spine syndrome (RSS). This disorder is usually associated with limited flexion of the spine, a relatively mild and slowly progressive myopathy, and elbow and ankle contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/43\">",
"     43",
"    </a>",
"    ]. Cardiomyopathy has not been observed. Early and severe scoliosis in the first decade is in favor of RSS. Severe respiratory involvement is usually present in RSS but is unusual in EDMD (",
"    <a class=\"graphic graphic_algorithm graphicRef52444 \" href=\"UTD.htm?21/21/21841\">",
"     algorithm 1",
"    </a>",
"    ). Patients with LMNA-related congenital muscular dystrophy may have prominent inflammatory changes on muscle biopsy and thus be misdiagnosed as having an inflammatory myopathy. In one series of 20 patients with early onset (age &le;2 years) inflammatory myopathy, heterozygous LMNA mutations were identified in 11 (55 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the selenoprotein N1 gene (SEPN1) have been identified in a subset of patients with RSS (RSMD1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link&amp;anchor=H12#H12\">",
"     \"Congenital myopathies\", section on 'Multiminicore disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no disease modifying therapy for EDMD. Management is supportive. Cardiomyopathy and conduction system defects are major problems, as discussed in the following section. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cardiac issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Physical therapy should focus on stretching exercises to prevent the early development of contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/24\">",
"     24",
"    </a>",
"    ]. Other interventions include orthopedic procedures to release contractures, spinal fusion for severe scoliosis, walking aids (eg, canes walkers, orthoses, wheelchairs) to facilitate mobility, and respiratory aids in the late stages of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiac issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal concern in the patient with EDMD is death resulting from cardiac involvement. The cardiac status of the patient should therefore be investigated even in asymptomatic patients at least once a year [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/24\">",
"     24",
"    </a>",
"    ]. Ambulatory arrhythmia monitoring should be considered in those with normal ECGs.",
"   </p>",
"   <p>",
"    Cardiac interventions may be required to treat arrhythmias, heart failure, and conduction defects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/24\">",
"     24",
"    </a>",
"    ]. Placement of a cardiac pacemaker or an implantable cardioverter defibrillator can be lifesaving in patients with evidence of atrioventricular block [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac transplantation may be an option in selected patients with EDMD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential problems related to anesthesia should be anticipated for patients with EDMD undergoing surgery, which may be required to manage orthopedic complications of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/24,46\">",
"     24,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac pacing (temporary or permanent) should be available perioperatively.",
"     </li>",
"     <li>",
"      Anesthetic agents with myocardial depressant activity should be avoided in patients with significant cardiomyopathy.",
"     </li>",
"     <li>",
"      Neck flexion may be markedly reduced, causing difficulty with endotracheal intubation.",
"     </li>",
"     <li>",
"      Flexion contractures of the cervical and lumbar paravertebral muscles may interfere with spinal and epidural anesthesia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      is contraindicated because patients with degenerative or dystrophic neuromuscular disease are at increased risk for the development of severe hyperkalemia.",
"     </li>",
"     <li>",
"      Rhabdomyolysis, hyperkalemia, or other catabolic reactions in muscle have not been described in EDMD. However, episodes that mimic malignant hyperthermia have been reported in other muscular dystrophies and neuromuscular disorders, with clinical manifestations that include rhabdomyolysis, hyperkalemia, and sudden cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21415/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. Thus, we recommend avoidance of potential triggering agents such as depolarizing muscle relaxants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      ) and volatile anesthetic drugs (eg, halothane,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"       isoflurane",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"       desflurane",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"       sevoflurane",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=see_link\">",
"       \"Patient information: Muscular dystrophy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=see_link\">",
"       \"Patient information: Overview of muscular dystrophies (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of symptoms from Emery-Dreifuss muscular dystrophy (EDMD) is usually in the first or second decade of life. The major features are early contractures, slowly progressive humeroperoneal muscle",
"      <span class=\"nowrap\">",
"       weakness/wasting,",
"      </span>",
"      and a dilated cardiomyopathy associated with atrioventricular conduction abnormalities. The disease exhibits significant variability both within and between families. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings in EDMD include elevation of serum creatine kinase (typically modest but sometimes severe), ECG abnormalities (eg, atrioventricular block, small T waves, atrial arrhythmias), and myopathic features on electromyogram and muscle biopsy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are X-linked, autosomal dominant, and autosomal recessive forms of EDMD. The X-linked forms are caused by mutations of the EMD gene (EDMD1) that encodes a protein named emerin, and by mutations of the FHL1 gene (EDMD6) that encodes the FHL1A protein. Both the autosomal dominant (EDMD2) and the rare autosomal recessive (EDMD3) forms are linked to mutations of the LMNA gene that encodes for lamin",
"      <span class=\"nowrap\">",
"       A/C.",
"      </span>",
"      Mutations in other nuclear membrane protein genes such as SYNE1 (EDMD4) and SYNE2 (EDMD5) have been detected in families with EDMD-like phenotypes and autosomal dominant inheritance. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases with typical clinical features of EDMD and a supportive family history, genetic testing may confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no disease modifying therapy for EDMD. Management is supportive. Cardiac interventions may be required to treat arrhythmias, heart failure, and conduction defects. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Cardiac issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential problems related to anesthesia should be anticipated for patients with EDMD undergoing surgery. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/1\">",
"      Emery AE. Emery-Dreifuss muscular dystrophy - a 40 year retrospective. Neuromuscul Disord 2000; 10:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/2\">",
"      Hopkins LC, Jackson JA, Elsas LJ. Emery-dreifuss humeroperoneal muscular dystrophy: an x-linked myopathy with unusual contractures and bradycardia. Ann Neurol 1981; 10:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/3\">",
"      Rakovec P, Zidar J, Sinkovec M, et al. Cardiac involvement in Emery-Dreifuss muscular dystrophy: role of a diagnostic pacemaker. Pacing Clin Electrophysiol 1995; 18:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/4\">",
"      Sakata K, Shimizu M, Ino H, et al. High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene. Circulation 2005; 111:3352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/5\">",
"      Yates JR, Wehnert M. The Emery-Dreifuss Muscular Dystrophy Mutation Database. Neuromuscul Disord 1999; 9:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/6\">",
"      Manilal S, Sewry CA, Man N, et al. Diagnosis of X-linked Emery-Dreifuss muscular dystrophy by protein analysis of leucocytes and skin with monoclonal antibodies. Neuromuscul Disord 1997; 7:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/7\">",
"      Mora M, Cartegni L, Di Blasi C, et al. X-linked Emery-Dreifuss muscular dystrophy can be diagnosed from skin biopsy or blood sample. Ann Neurol 1997; 42:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/8\">",
"      Carboni N, Mura M, Marrosu G, et al. Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by LMNA gene mutations. Muscle Nerve 2010; 41:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/9\">",
"      Puckelwartz M, McNally EM. Emery-Dreifuss muscular dystrophy. Handb Clin Neurol 2011; 101:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/10\">",
"      Worman HJ, Ostlund C, Wang Y. Diseases of the nuclear envelope. Cold Spring Harb Perspect Biol 2010; 2:a000760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/11\">",
"      Yates JR, Warner JP, Smith JA, et al. Emery-Dreifuss muscular dystrophy: linkage to markers in distal Xq28. J Med Genet 1993; 30:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/12\">",
"      Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994; 8:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/13\">",
"      Nagano A, Koga R, Ogawa M, et al. Emerin deficiency at the nuclear membrane in patients with Emery-Dreifuss muscular dystrophy. Nat Genet 1996; 12:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/14\">",
"      Tsuchiya Y, Hase A, Ogawa M, et al. Distinct regions specify the nuclear membrane targeting of emerin, the responsible protein for Emery-Dreifuss muscular dystrophy. Eur J Biochem 1999; 259:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/15\">",
"      Gueneau L, Bertrand AT, Jais JP, et al. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2009; 85:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/16\">",
"      Windpassinger C, Schoser B, Straub V, et al. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet 2008; 82:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/17\">",
"      Cowling BS, Cottle DL, Wilding BR, et al. Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features. Neuromuscul Disord 2011; 21:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/18\">",
"      Selcen D, Bromberg MB, Chin SS, Engel AG. Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy. Neurology 2011; 77:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/19\">",
"      Raffaele Di Barletta M, Ricci E, Galluzzi G, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000; 66:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/20\">",
"      Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999; 21:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/21\">",
"      Jimenez-Escrig A, Gobernado I, Garcia-Villanueva M, Sanchez-Herranz A. Autosomal recessive Emery-Dreifuss muscular dystrophy caused by a novel mutation (R225Q) in the lamin A/C gene identified by exome sequencing. Muscle Nerve 2012; 45:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/22\">",
"      Zhang Q, Bethmann C, Worth NF, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 2007; 16:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/23\">",
"      Liang WC, Mitsuhashi H, Keduka E, et al. TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy. Ann Neurol 2011; 69:1005.",
"     </a>",
"    </li>",
"    <li>",
"     Bonne G, Leturcq F, Ben Yaou R. Emery-Dreifuss muscular dystrophy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1436/ (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/25\">",
"      Bonne G, Yaou RB, B&eacute;roud C, et al. 108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. Neuromuscul Disord 2003; 13:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/26\">",
"      Muchir A, Bonne G, van der Kooi AJ, et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 2000; 9:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/27\">",
"      Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/28\">",
"      B&eacute;cane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 2000; 23:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/29\">",
"      Forissier JF, Bonne G, Bouchier C, et al. Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. Eur J Heart Fail 2003; 5:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/30\">",
"      Charniot JC, Pascal C, Bouchier C, et al. Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. Hum Mutat 2003; 21:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/31\">",
"      Quijano-Roy S, Mbieleu B, B&ouml;nnemann CG, et al. De novo LMNA mutations cause a new form of congenital muscular dystrophy. Ann Neurol 2008; 64:177.",
"     </a>",
"    </li>",
"    <li>",
"     Darras, BT. Unpublished observations, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/33\">",
"      Komaki H, Hayashi YK, Tsuburaya R, et al. Inflammatory changes in infantile-onset LMNA-associated myopathy. Neuromuscul Disord 2011; 21:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/34\">",
"      De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002; 70:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/35\">",
"      Shackleton S, Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000; 24:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/36\">",
"      Novelli G, Muchir A, Sangiuolo F, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 2002; 71:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/37\">",
"      De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/38\">",
"      Muntoni F, Bonne G, Goldfarb LG, et al. Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. Brain 2006; 129:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/39\">",
"      Ben Yaou R, Toutain A, Arimura T, et al. Multitissular involvement in a family with LMNA and EMD mutations: Role of digenic mechanism? Neurology 2007; 68:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/40\">",
"      Manilal S, Recan D, Sewry CA, et al. Mutations in Emery-Dreifuss muscular dystrophy and their effects on emerin protein expression. Hum Mol Genet 1998; 7:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/41\">",
"      Menache CC, Brown CA, Donnelly JH, et al. Identification of a novel truncating mutation (S171X) in the Emerin gene in five members of a Caucasian American family with Emery-Dreifuss muscular dystrophy. Hum Mutat 2000; 16:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/42\">",
"      Brown CA, Lanning RW, McKinney KQ, et al. Novel and recurrent mutations in lamin A/C in patients with Emery-Dreifuss muscular dystrophy. Am J Med Genet 2001; 102:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/43\">",
"      Dubowitz V. Rigid spine syndrome: a muscle syndrome in search of a name. Proc R Soc Med 1973; 66:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/44\">",
"      Golzio PG, Chiribiri A, Gaita F. 'Unexpected' sudden death avoided by implantable cardioverter defibrillator in Emery Dreifuss patient. Europace 2007; 9:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/45\">",
"      Dell'Amore A, Botta L, Martin Suarez S, et al. Heart transplantation in patients with Emery-Dreifuss muscular dystrophy: case reports. Transplant Proc 2007; 39:3538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/46\">",
"      Aldwinckle RJ, Carr AS. The anesthetic management of a patient with Emery-Dreifuss muscular dystrophy for orthopedic surgery. Can J Anaesth 2002; 49:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/47\">",
"      Takagi A, Nakase H. Malignant hyperthermia-like reactions in Duchenne or Becker muscular dystrophy: review and hypothesis. Rinsho Shinkeigaku 2008; 48:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/48\">",
"      Wedel DJ. Malignant hyperthermia and neuromuscular disease. Neuromuscul Disord 1992; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21415/abstract/49\">",
"      Heiman-Patterson TD, Natter HM, Rosenberg HR, et al. Malignant hyperthermia susceptibility in X-linked muscle dystrophies. Pediatr Neurol 1986; 2:356.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6185 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21415=[""].join("\n");
var outline_f20_58_21415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      X-linked forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autosomal dominant and recessive forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laminopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiac issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6185\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6185|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/21/21841\" title=\"algorithm 1\">",
"      Evaluation early contractures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=related_link\">",
"      Congenital myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=related_link\">",
"      Facioscapulohumeral muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=related_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=related_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=related_link\">",
"      Patient information: Muscular dystrophy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=related_link\">",
"      Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_58_21416="Parathyroid hormone assays and their clinical use";
var content_f20_58_21416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parathyroid hormone assays and their clinical use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21416/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21416/contributors\">",
"     Ghada El-Hajj Fuleihan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21416/contributors\">",
"     Harald J&uuml;ppner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21416/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21416/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/58/21416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid hormone (PTH) 1-84 is the biologically active hormone produced by the parathyroid glands and secreted into the systemic circulation. It exerts its effects through the interaction of its first 34 amino acids with the type 1",
"    <span class=\"nowrap\">",
"     PTH/PTHrP",
"    </span>",
"    receptor (PTHR1). PTH fragments, containing carboxyl-(C) or amino-terminal (N-terminal) portions of the molecule that arise from either intraglandular or peripheral degradation of the hormone, are also present in the circulation.",
"   </p>",
"   <p>",
"    PTH 1-84 has a plasma half-life of two to four minutes. In comparison, the C-terminal fragments, which are cleared principally by the kidney, have a half-life that is 5 to 10 times longer. As a result, circulating immunoreactive PTH in normocalcemic subjects comprises:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PTH 1-84 &mdash; 5 to 30 percent",
"     </li>",
"     <li>",
"      C-terminal fragments &mdash; 70 to 95 percent",
"     </li>",
"     <li>",
"      N-terminal fragments &mdash; a small percentage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increasing body of evidence suggests that some of these fragments, particularly the N-terminally truncated fragment PTH 7-84 (also referred to as non-PTH 1-84), interact with distinct receptors (C-PTH receptor, C-PTHR) and thereby may have important roles in the regulation of bone resorption and serum calcium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/1\">",
"     1",
"    </a>",
"    ]. It is therefore conceivable that quantification of different PTH fragments could add to the diagnostic importance of PTH measurements.",
"   </p>",
"   <p>",
"    PTH assays and their clinical use will be reviewed here. Parathyroid hormone physiology, receptor binding, and actions are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=see_link\">",
"     \"Parathyroid hormone secretion and action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PTH ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioimmunoassays for the detection of PTH are referred to as \"first\" generation assays; consequently, immunometric assays (IMAs) are referred to as \"second\" and \"third\" generation assays, respectively. The traditional second generation assays (known as intact PTH assays) measure PTH 1-84 and other large C-terminal PTH fragments, whereas the third generation assays (bioactive or biointact PTH assays) only detect PTH 1-84 and not C-terminal fragments. However, some authorities refer to the immunometric assays as first generation IMA (intact PTH assays) and second generation IMA (bioactive or biointact PTH assays).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radioimmunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTH was first measured by radioimmunoassay (RIA) using different polyclonal antibodies directed against epitopes that proved to be predominantly within the mid- or carboxyl-terminal (C-terminal) portion of the PTH molecule (",
"    <a class=\"graphic graphic_figure graphicRef50424 \" href=\"UTD.htm?43/31/44528\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Such first generation PTH assays therefore detected predominantly PTH fragments that lack an intact amino-terminus (N-terminus), do not activate the",
"    <span class=\"nowrap\">",
"     PTH/PTHrP",
"    </span>",
"    receptor, and thus do not mediate the hormone's calcemic actions. Because of the cross-reactivity with hormonal fragments and insufficient sensitivity, such assays have now been largely replaced by two-site immunometric assays (IMA), also referred to as \"sandwich\" assays [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunometric assays for the detection of PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunometric assays (IMAs) utilize two different antibodies that are directed against distinct epitopes within the PTH molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. One of these antibodies, directed against a region within the C-terminus, captures circulating PTH 1-84 as well as PTH fragments. The second antibody, directed against an N-terminal epitope, serves as the detection antibody, which can be radioiodinated, biotinylated for detection with enzyme-linked avidin, or tagged otherwise (",
"    <a class=\"graphic graphic_figure graphicRef50424 \" href=\"UTD.htm?43/31/44528\">",
"     figure 1",
"    </a>",
"    ). The radiolabeled detection antibody has been replaced in most commercially available assays with a non-radioactively tagged antibody. IMA assays are intrinsically more sensitive and specific than RIAs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, they provide excellent sensitivity and specificity even for the diagnosis of mild forms of primary hyperparathyroidism. Furthermore, in contrast to the findings with RIAs, concentrations of PTH measured by IMAs are usually below the normal range in most patients with humoral hypercalcemia of malignancy and with different forms of hypo- and pseudohypoparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Intact PTH assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first widely used IMA two-site sandwich assays, also known as \"intact PTH\" assays, use a capture antibody against the C-terminal part of the PTH molecule (epitopes 39-84) and a radioiodinated detection antibody directed towards the N-terminal portion of PTH (epitopes 13-34), and therefore detects the intact as well as large C-terminal fragments that lack portions of the N-terminus (that is the first 12 amino) and are termed non-PTH 1-84 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Non-parathyroid hormone 1-84'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The detailed characterization of this intact PTH assay showed that the detection antibody interacts not only with human PTH 1-34 and PTH 2-34, but also with PTH fragments that are truncated further at the N-terminus, such as PTH 7-84 (",
"    <a class=\"graphic graphic_figure graphicRef50424 \" href=\"UTD.htm?43/31/44528\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/13\">",
"     13",
"    </a>",
"    ]. The latter fragments (or variants thereof) are biologically inactive with regards to calcium-regulating activity, but some appear to inhibit osteoclastic bone resorption and the formation of mature osteoclasts, and thus may have indirect hypocalcemic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bioactive PTH 1-84 assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent IMA two-site assays use a similar capture antibody as the intact PTH assays but use detection antibodies directed against epitopes at the extreme N-terminal end (epitopes 1-4) of the molecule, and therefore were believed to detect exclusively the biologically active PTH 1-84 (whole PTH or bioactive PTH), but not non-PTH 1-84 fragments (",
"    <a class=\"graphic graphic_figure graphicRef50424 \" href=\"UTD.htm?43/31/44528\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/13,15-18\">",
"     13,15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a study comparing a radioimmunoassay with intact and bioactive PTH immunoassays in normal and hyperparathyroid subjects, the bioactive PTH assay reacted with PTH 1-84 and with another N-terminal PTH fragment, which is not recognized by the intact PTH assays [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/11\">",
"     11",
"    </a>",
"    ]. The biological significance of this fragment, called N-terminal PTH form (N-PTH), is uncertain. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'N-terminal PTH form'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12991203\">",
"    <span class=\"h3\">",
"     Assay variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is inherent biologic variability in PTH levels due to changes in calcium intake and renal function. In addition, there is currently no reference method for the measurement of PTH and no recombinant or synthetic PTH standard that is shared by different PTH assays. Consequently, results in PTH levels may vary even when using PTH assays of the same generation that are produced by different manufacturers. This finding underscores the importance of defining assay-specific normative ranges, particularly in certain populations (eg, chronic kidney disease), and basing decisions regarding treatment upon trends rather than single laboratory values [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunometric assays, including the different PTH assays, are vulnerable to interference with heterophile antibodies, which can be present in up to 11 percent of the population, that can bridge the capture and signal antibodies and cause a false-positive result. Such antibodies are increasingly prevalent because of the rise in the use of monoclonal antibodies in the treatment of inflammatory disorders, cancer, and transplantation. Such antibodies were shown to cause substantial elevation in PTH levels in a 36-year-old woman with history of renal osteodystrophy, a functioning renal allograft, and PTH excess (3374",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    refractory to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/20\">",
"     20",
"    </a>",
"    ]. She presented for consideration of a third parathyroidectomy, but PTH levels did not decline postoperatively, and the patient developed severe hypocalcemia. Reanalysis of the patient&rsquo;s serum specimens was performed with heterophile blocking agents to the murine-based immunoassay and revealed her true PTH level to be 5",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    The stability of PTH when stored as serum or plasma EDTA samples at -80&deg;C is not indefinite. Depending upon the assay, the maximum storage times with either dry or EDTA tubes ranges from two months to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/21\">",
"     21",
"    </a>",
"    ]. The purported greater stability of PTH when measured with a third generation assay may be an added advantage, which has prompted clinical chemistry laboratories to use third generation assays instead of &ldquo;intact&rdquo; assays [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     PTH fragments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of circulating molecular forms of PTH have been identified by radioimmunoassays and immunometric assays (",
"    <a class=\"graphic graphic_figure graphicRef50424 \" href=\"UTD.htm?43/31/44528\">",
"     figure 1",
"    </a>",
"    ). Carboxyl-terminal (C-terminal) fragments (lacking small or large portions of the N-terminus) are most abundant, representing approximately 80 percent of circulating PTH in healthy individuals and approximately 95 percent in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/23\">",
"     23",
"    </a>",
"    ]. Large C-terminal fragments with a partially preserved N-terminus (referred to as non-parathyroid hormone 1-84) are secreted in vitro by parathyroid tissue from patients with primary and secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/12,24,25\">",
"     12,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An amino-terminal (N-terminal) form of PTH that is distinct from PTH 1-84 but detectable by bioactive PTH assays has also been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/11\">",
"     11",
"    </a>",
"    ]. This form is secreted in vitro by parathyroid tissue from patients with primary and secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/11,26\">",
"     11,26",
"    </a>",
"    ]. In one report, a biologically active N-terminal PTH fragment (PTH 1-52) was identified in the parathyroid adenoma of a patient with primary hyperparathyroidism, who had undetectable serum intact PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not all of the large PTH fragments have yet been defined, PTH 7-84 appears to be a dominant form, and it may have hypocalcemic properties and may affect the activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maturation of bone-resorbing osteoclasts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Non-parathyroid hormone 1-84",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-PTH 1-84 fragments are a subset of large C-terminal fragments that lack only a small portion of the N-terminus, and are therefore measured by the intact PTH assay. They differ from other C-terminal fragments that lack a large portion of the N-terminus and are not detected by the intact PTH assay. In individuals with normal renal function, non-PTH 1-84 fragments account for 10 percent of all C-terminal PTH fragments and for 20 percent of the PTH detected by the intact PTH assay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In patients with chronic kidney disease, such as in patients on hemodialysis, non-PTH 1-84 may account for as much as 45 percent of the immunoreactivity measured by the intact PTH assay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predominant non-PTH 1-84 isoform is PTH 7-84. PTH 7-84 does not bind efficiently to the type 1",
"    <span class=\"nowrap\">",
"     PTH/PTHrP",
"    </span>",
"    receptor (PTHR1). Instead, it presumably exerts some of its biological effects through a receptor specific for the carboxyl-terminal portion of PTH (C-PTH receptor) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/14,29\">",
"     14,29",
"    </a>",
"    ]. Such receptors have been detected in several different tissues and in clonal cell lines, including ROS",
"    <span class=\"nowrap\">",
"     17/2.8",
"    </span>",
"    cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]; the most abundant concentrations of this receptor were detected on osteocytic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/35\">",
"     35",
"    </a>",
"    ]. PTH 7-84, but not PTH 3-34 or PTHrP 7-36, inhibits basal 45Ca-release from pre-labeled calvarial bones. In addition, PTH 7-84 inhibits bone resorption induced by a variety of osteoclast-activating agents such as 1,25-dihydroxyvitamin D, prostaglandin E2, and IL-11 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synthetic PTH 7-84 has been shown to have hypocalcemic properties when tested in vivo, as evidenced by its ability to block the calcemic actions of PTH 1-34 and PTH 1-84 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/16,29\">",
"     16,29",
"    </a>",
"    ]. In addition, one study showed that PTH 7-84 decreased PTH-stimulated bone turnover in rats with moderate renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, PTH 7-84 seems to exert effects that are the opposite of those of PTH 1-84. This may contribute to the skeletal resistance to PTH that is observed in patients with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     N-terminal PTH form",
"    </span>",
"    &nbsp;&mdash;&nbsp;The existence of a modified form of PTH 1-84, referred to as N-terminal PTH (N-PTH), has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/11\">",
"     11",
"    </a>",
"    ]. It differs from PTH 1-84 in that it is poorly reactive with antibodies directed against epitopes 12-18 used in most intact PTH assays. In contrast, N-PTH is detected with third generation bioactive PTH assays (detection antibody requires amino acid residues 1 and 2) (",
"    <a class=\"graphic graphic_figure graphicRef50424 \" href=\"UTD.htm?43/31/44528\">",
"     figure 1",
"    </a>",
"    ). In individuals with normal renal function, N-PTH accounts for 4 to 8 percent of PTH detected with a bioactive PTH assay, whereas it accounts for up to 15 percent in patients with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. N-PTH appears to be overproduced in some forms of primary and secondary hyperparathyroidism and in parathyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/11,26,38\">",
"     11,26,38",
"    </a>",
"    ]. At the present time, its biological activity is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL USE OF PTH ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The realization that different circulating forms of PTH are detected by the various PTH assays has led to a re-assessment of these assays in conditions of increased and decreased PTH secretion. Available evidence suggests that bioactive or whole PTH assays provide little additional information from that provided by intact PTH assays for the diagnosis of primary hyperparathyroidism. However, some data suggest that the newer assays may be superior in patients with renal failure, for intraoperative PTH monitoring, and for making the initial diagnosis in patients with primary hyperparathyroidism and inappropriately \"normal\" serum PTH concentrations measured with intact PTH assays [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/13,15,39\">",
"     13,15,39",
"    </a>",
"    ]. It has also been shown to improve diagnostic accuracy in patients with PTH carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct comparison of the two immunometric PTH assays, the intact PTH assay for combined measurement of PTH 1-84 and non-PTH 1-84 and the bioactive PTH assay for the measurement of PTH 1-84 and N-terminal PTH, revealed an excellent correlation (r = 0.922) in 165 patients with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/15\">",
"     15",
"    </a>",
"    ]. Similar findings were reported in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/39,41-43\">",
"     39,41-43",
"    </a>",
"    ]. However, when using bioactive assays, overlap exists in the upper end of the normal range between individuals considered to be healthy and patients with surgically proven hyperparathyroidism.",
"   </p>",
"   <p>",
"    Although limited data [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/39\">",
"     39",
"    </a>",
"    ] suggest that PTH is increased in a higher proportion of patients with primary hyperparathyroidism when using the bioactive PTH assay, several other studies have found no improvement in diagnostic utility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Thus, either intact or bioactive PTH assays can be used for diagnosis of hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Measurement of PTH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The performance of bioactive PTH assays in patients with normocalcemic hyperparathyroidism requires further elucidation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intraoperative PTH assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid measurement of PTH levels is now frequently used intra-operatively to confirm that an adenoma has been successfully removed; this technique is used particularly during less invasive procedures involving limited neck exploration after pre-operative localization of the putative adenoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of PTH levels in 74 patients with primary hyperparathyroidism, which were performed in samples obtained 5, 10, and 15 minutes after excision of the adenoma, revealed that PTH, as measured with a bioactive assay, decreased faster after excision than when measured with the intact assay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. At five minutes, PTH levels had dropped to less than 50 percent of the level before parathyroidectomy in all patients using the bioactive assay, but remained above that cut-off in six patients (8 percent) using the intact assay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/45\">",
"     45",
"    </a>",
"    ]. Currently, most available rapid intraoperative assays are intact PTH assays measuring both PTH 1-84 and PTH 7-84, but it is conceivable that a third generation rapid assay measuring bioactive PTH may be more useful for monitoring during parathyroidectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Secondary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic kidney disease (CKD), parathyroid hormone concentrations are often measured to diagnose and monitor renal bone disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Renal osteodystrophy'",
"    </a>",
"    .) Although there is an excellent correlation between intact and bioactive PTH assays (r = 0.977) in patients with chronic kidney disease (CKD) on maintenance dialysis, mean PTH levels are typically about 50 percent lower when assessed by the bioactive assay compared with the intact assay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/13,15,18,47-50\">",
"     13,15,18,47-50",
"    </a>",
"    ]. This discrepancy is due to the large carboxyl-terminal PTH fragments, detected by intact PTH assays, which accumulate in patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/8-10,15,25\">",
"     8-10,15,25",
"    </a>",
"    ]. In some studies, a reduction in GFR across the spectrum of CKD is associated with a preferential increase in non-PTH 1-84, rather than PTH 1-84, resulting in a decrease in the ratio of PTH",
"    <span class=\"nowrap\">",
"     1-84/non-PTH",
"    </span>",
"    1-84 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because some of these naturally occurring PTH fragments have biologic activity distinct from that of PTH 1-84 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/14,16,29\">",
"     14,16,29",
"    </a>",
"    ], an independent assessment of PTH 1-84 and non-PTH 1-84 fragments may increase the diagnostic sensitivity to predict the form of bone disease in patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Although one study suggested that the calculated ratio of PTH 1-84 (measured by the bioactive PTH assay) to non-PTH 1-84 (difference between the results obtained with intact and bioactive PTH assays) may provide a better prediction of bone turnover than each measurement alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/47\">",
"     47",
"    </a>",
"    ], similar studies by others are thus far unable to confirm these findings using either bone histomorphometry or biochemical markers of bone remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/5,17,18,48,49,55-59\">",
"     5,17,18,48,49,55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Kidney Foundation Dialysis Outcome Quality and Improving Global Outcomes",
"    <span class=\"nowrap\">",
"     (K/DOQI",
"    </span>",
"    and KDIGO) practice guidelines were formulated to help optimally manage secondary hyperparathyroidism and mineral metabolism abnormalities in patients with CKD. Most of the clinical data related to normal and abnormal conditions of parathyroid hormone secretion, including renal osteodystrophy, are based upon levels derived from the intact PTH assay. As a result,",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines are based upon PTH determinations performed by the intact PTH assay. However, there are data suggesting significant variability with PTH results among the different available assays, as well marked differences based on sample collection and storage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, the KDIGO guidelines recommend against targets based upon absolute PTH levels found in one assay. Instead, they suggest maintaining intact PTH levels between approximately two to nine times the upper normal limit for the assay that is being used for patients undergoing dialysis. This requires the clinician to be aware of the particular assay and normal values associated with its use. These guidelines are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pseudohypoparathyroidism (PHP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohypoparathyroidism (PHP) refers to a group of heterogeneous disorders defined by unresponsiveness to PTH in the proximal renal tubules and characterized biochemically by hypocalcemia and hyperphosphatemia with elevated PTH concentrations. In patients with pseudohypoparathyroidism (PHP) type 1, there is diminished urinary cyclic AMP excretion in response to exogenous PTH administration due to a deficiency in the proximal renal tubules of the alpha subunit of the stimulatory G protein (Gs-alpha) that couples to the PTH receptor (PTHR1).",
"   </p>",
"   <p>",
"    There are several subtypes of PHP type 1 that are caused by heterozygous mutations within or up-stream of GNAS, the gene encoding Gs-alpha. PHP type 1a (PHP-1a) is an autosomal dominant disease caused by maternally inherited loss-of-function mutations located in GNAS exons 1-13 that cause PTH resistance in the proximal renal tubules, where Gs-alpha is derived only from the maternal allele. PHP type 1b (PHP-1b), on the other hand, is caused by microdeletions within or up-stream of GNAS that are associated with the loss of methylation at one or several differentially methylated regions within GNAS, or in rare instances, by paternal uniparental isodisomy involving chromosome 20q. Pseudohypoparathyroidism is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology of hypocalcemia in infants and children\", section on 'End-organ resistance/pseudohypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ratio of non-PTH 1-84 to PTH 1-84 has been shown to be higher in patients with PHP-Ia and PHP-Ib than in 53 healthy controls (0.56&plusmn;0.07 versus 0.30&plusmn;0.11) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/60\">",
"     60",
"    </a>",
"    ], suggesting that non-PTH 1-84 fragments, which may be similar to PTH 7-84, could be sufficiently elevated to reduce the response of a target organ to PTH in this group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21416/abstract/60\">",
"     60",
"    </a>",
"    ]. Given the putative hypocalcemic properties of PTH 7-84, it is thus conceivable that the accumulation of non-PTH 1-84 fragments contributes to the pathophysiology of PTH-resistant hypocalcemia in PHP. However, these observations require further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PTH was first measured by radioimmunoassay (RIA) using different polyclonal antibodies directed against epitopes that proved to be located predominantly within the mid- or carboxyl-terminal (C-terminal) portion of the PTH molecule. Radioimmunoassays have been largely replaced by two-site immunometric assays (IMA), which provide improved sensitivity and specificity for the diagnosis of mild forms of primary hyperparathyroidism, humoral hypercalcemia of malignancy, and different forms of hypo- and pseudohypoparathyroidism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'PTH assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inter-method variability in PTH measurement can lead to differing therapeutic decisions in an individual patient, depending on the PTH assay used. Thus, it is important to define assay specific normative ranges, particularly in certain populations (eg, chronic kidney disease). (See",
"      <a class=\"local\" href=\"#H12991203\">",
"       'Assay variability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although PTH 1-84 is thought to be the biologically active hormone produced by the parathyroid glands, a number of other circulating PTH molecular forms have been identified by radioimmunoassays and by immunometric assays that may have biologic activity (",
"      <a class=\"graphic graphic_figure graphicRef50424 \" href=\"UTD.htm?43/31/44528\">",
"       figure 1",
"      </a>",
"      ). The development of additional PTH assays, particularly those distinguishing circulating hormonal fragments, are likely to further improve their diagnostic utility for disorders caused by abnormal parathyroid secretion or action. Fragment-specific assays may also allow insight into the relative contribution of PTH and its fragments to mineral homeostasis in normal and pathophysiological conditions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'PTH fragments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Either intact or bioactive PTH assays can be used for establishing the diagnosis of hyperparathyroidism and for the diagnosis and monitoring of renal bone disease. The clinician must be aware of the particular assay and normal values associated with its use. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical use of PTH assays'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Target goals'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\", section on 'Goal target levels'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/1\">",
"      Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 2005; 26:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/2\">",
"      Berson SA, Yalow RS, Aurbach GD, Potts JT. IMMUNOASSAY OF BOVINE AND HUMAN PARATHYROID HORMONE. Proc Natl Acad Sci U S A 1963; 49:613.",
"     </a>",
"    </li>",
"    <li>",
"     Segre GV, Potts JT Jr. Differential diagnosis of hypercalcemia. In: Endocrinology, DeGroot LJ (Ed), WB Saunders, Philadelphia 1995. p.1075.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/4\">",
"      Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/5\">",
"      Goodman WG, J&uuml;ppner H, Salusky IB, Sherrard DJ. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int 2003; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/6\">",
"      Martin KJ, Akhtar I, Gonz&aacute;lez EA. Parathyroid hormone: new assays, new receptors. Semin Nephrol 2004; 24:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/7\">",
"      Ekins R. More sensitive immunoassays. Nature 1980; 284:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/8\">",
"      Brossard JH, Cloutier M, Roy L, et al. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996; 81:3923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/9\">",
"      Lepage R, Roy L, Brossard JH, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/10\">",
"      Brossard JH, Lepage R, Cardinal H, et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000; 46:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/11\">",
"      D'Amour P, Brossard JH, Rousseau L, et al. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003; 49:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/12\">",
"      D'Amour P, Brossard JH, R&auml;kel A, et al. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 2005; 51:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/13\">",
"      John MR, Goodman WG, Gao P, et al. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999; 84:4287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/14\">",
"      Divieti P, John MR, J&uuml;ppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002; 143:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/15\">",
"      Gao P, Scheibel S, D'Amour P, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/16\">",
"      Slatopolsky E, Finch J, Clay P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/17\">",
"      Salusky IB, Goodman WG, Kuizon BD, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/18\">",
"      Savoca R, Bock A, Kraenzlin ME, et al. An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease. Clin Chim Acta 2004; 343:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/19\">",
"      Joly D, Drueke TB, Alberti C, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008; 51:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/20\">",
"      Levin O, Morris LF, Wah DT, et al. Falsely elevated plasma parathyroid hormone level mimicking tertiary hyperparathyroidism. Endocr Pract 2011; 17:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/21\">",
"      Cavalier E, Delanaye P, Hubert P, et al. Estimation of the stability of parathyroid hormone when stored at -80 degrees C for a long period. Clin J Am Soc Nephrol 2009; 4:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/22\">",
"      Cavalier E, Carlisi A, Bekaert AC, et al. New insights on the stability of the parathyroid hormone as assayed by an automated 3rd generation PTH assay. Clin Chim Acta 2012; 413:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/23\">",
"      D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int Suppl 2006; :S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/24\">",
"      D'Amour P, Brossard JH, Rousseau L, et al. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005; 68:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/25\">",
"      Kunii IS, Vieira JG. Circulating forms of parathyroid hormone detected with an immunofluorometric assay in patients with primary hyperparathyroidism and in hyperparathyroidism secondary to chronic renal failure. Braz J Med Biol Res 2001; 34:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/26\">",
"      R&auml;kel A, Brossard JH, Patenaude JV, et al. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol (Oxf) 2005; 62:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/27\">",
"      Au AY, McDonald K, Gill A, et al. PTH mutation with primary hyperparathyroidism and undetectable intact PTH. N Engl J Med 2008; 359:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/28\">",
"      Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/29\">",
"      Nguyen-Yamamoto L, Rousseau L, Brossard JH, et al. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001; 142:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/30\">",
"      Inomata N, Akiyama M, Kubota N, J&uuml;ppner H. Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 1995; 136:4732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/31\">",
"      Demay M, Mitchell J, Goltzman D. Comparison of renal and osseous binding of parathyroid hormone and hormonal fragments. Am J Physiol 1985; 249:E437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/32\">",
"      McKee MD, Murray TM. Binding of intact parathyroid hormone to chicken renal plasma membranes: evidence for a second binding site with carboxyl-terminal specificity. Endocrinology 1985; 117:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/33\">",
"      Murray TM, Rao LG, Muzaffar SA. Dexamethasone-treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide hPTH (53-84): stimulation of alkaline phosphatase. Calcif Tissue Int 1991; 49:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/34\">",
"      Rao LG, Murray TM. Binding of intact parathyroid hormone to rat osteosarcoma cells: major contribution of binding sites for the carboxyl-terminal region of the hormone. Endocrinology 1985; 117:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/35\">",
"      Divieti P, Inomata N, Chapin K, et al. Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. Endocrinology 2001; 142:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/36\">",
"      Langub MC, Monier-Faugere MC, Wang G, et al. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 2003; 144:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/37\">",
"      Wesseling-Perry K, Harkins GC, Wang HJ, et al. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab 2010; 95:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/38\">",
"      Rubin MR, Silverberg SJ, D'Amour P, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem 2007; 53:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/39\">",
"      Silverberg SJ, Gao P, Brown I, et al. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:4725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/40\">",
"      Cavalier E, Daly AF, Betea D, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 2010; 95:3745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/41\">",
"      Bouillon R, Coopmans W, Degroote DE, et al. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 1990; 36:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/42\">",
"      Carnevale V, Dionisi S, Nofroni I, et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004; 50:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/43\">",
"      Boudou P, Ibrahim F, Cormier C, et al. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:6370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/44\">",
"      Silverberg SJ, Bilezikian JP. \"Incipient\" primary hyperparathyroidism: a \"forme fruste\" of an old disease. J Clin Endocrinol Metab 2003; 88:5348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/45\">",
"      Yamashita H, Gao P, Cantor T, et al. Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery 2004; 135:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/46\">",
"      Yamashita H, Cantor T, Uchino S, et al. Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism. World J Surg 2005; 29:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/47\">",
"      Monier-Faugere MC, Geng Z, Mawad H, et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/48\">",
"      Kazama JJ, Omori T, Ei I, et al. Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia. Clin Exp Nephrol 2003; 7:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/49\">",
"      Lehmann G, Stein G, H&uuml;ller M, et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005; 68:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/50\">",
"      Melamed ML, Eustace JA, Plantinga LC, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008; 23:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/51\">",
"      Donadio C, Ardini M, Lucchesi A, et al. Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status? Clin Nephrol 2007; 67:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/52\">",
"      Herberth J, Fahrleitner-Pammer A, Obermayer-Pietsch B, et al. Changes in total parathyroid hormone (PTH), PTH-(1-84) and large C-PTH fragments in different stages of chronic kidney disease. Clin Nephrol 2006; 65:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/53\">",
"      Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure--an evolving disorder. Kidney Int 1993; 43:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/54\">",
"      Salusky IB, Coburn JW, Brill J, et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988; 33:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/55\">",
"      Coen G, Bonucci E, Ballanti P, et al. PTH 1-84 and PTH \"7-84\" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/56\">",
"      Inaba M, Okuno S, Imanishi Y, et al. Significance of Bio-intact PTH(1-84) assay in hemodialysis patients. Osteoporos Int 2005; 16:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/57\">",
"      Goodman WG. The evolution of assays for parathyroid hormone. Semin Dial 2005; 18:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/58\">",
"      Negri AL, Alvarez Quiroga M, Bravo M, et al. [Whole PTH and 1-84/84 PTH ratio for the non invasive determination of low bone turnover in renal osteodysthrophy]. Nefrologia 2003; 23:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/59\">",
"      Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21416/abstract/60\">",
"      Hatakeyama Y, Mizunashi K, Furukawa Y, et al. Plasma levels of parathyroid hormone (1-84) whole molecule and parathyroid hormone (7-84)-like fragments in pseudohypoparathyroidism type I. J Clin Endocrinol Metab 2003; 88:2250.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2055 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21416=[""].join("\n");
var outline_f20_58_21416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PTH ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radioimmunoassays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunometric assays for the detection of PTH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Intact PTH assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bioactive PTH 1-84 assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12991203\">",
"      - Assay variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PTH fragments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Non-parathyroid hormone 1-84",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - N-terminal PTH form",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL USE OF PTH ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intraoperative PTH assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Secondary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pseudohypoparathyroidism (PHP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2055|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/31/44528\" title=\"figure 1\">",
"      Parathyroid hormone structure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=related_link\">",
"      Etiology of hypocalcemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_58_21417="Clinical manifestations, diagnosis, and treatment of burn wound sepsis";
var content_f20_58_21417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of burn wound sepsis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21417/contributors\">",
"     Gerd G Gauglitz, MMS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21417/contributors\">",
"     Shahriar Shahrokhi, MD, FRCSC, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21417/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/58/21417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/58/21417/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/58/21417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H192003545\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who sustain a severe burn (&gt;20 percent total body surface area) are at a high risk of developing an invasive burn wound infection, also referred to as burn wound sepsis, which often leads to multi-organ dysfunction and death (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It is estimated that 75 percent of the mortality following thermal injuries is related directly to infection. Nosocomial infections (eg, central venous catheter source) and emerging multi-drug-resistant strains of bacteria and fungi contribute to burn wound infections, sepsis, and associated death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1,2,5-9\">",
"     1,2,5-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192006955\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are excellent criteria for the diagnosis of infection and sepsis in nonburned patients, but these criteria do not apply to severely burned patients because of the inflammatory mediators that alter the postburn baseline metabolic profile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standardized definitions for sepsis and infection that are specifically applicable to the burn patient were developed in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/6\">",
"     6",
"    </a>",
"    ]. The burn sepsis definition distinguishes the change in patient status as a result of a microbial infection from changes that occur secondary to the hypermetabolic response of the burn itself. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A noninvasive bacterial infection in the burn wound and eschar is defined as &gt;10",
"    <sup>",
"     5",
"    </sup>",
"    bacteria per gram of tissue. An invasive burn wound infection, also called burn wound sepsis, is defined as the presence of microorganisms in adjacent unburned tissue. Quantitative burn wound cultures and burn wound histopathology are required to establish the diagnosis of a bacterial infection.",
"   </p>",
"   <p>",
"    A noninvasive fungal infection is defined as the recovery of a mold or yeast by culture of a specimen obtained from a burn wound or eschar. An invasive fungal disease is diagnosed by identifying hyphae or melanized yeast-like forms using histopathologic, cytopathologic, or direct microscopic examination of a needle aspiration or biopsy specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/10\">",
"     10",
"    </a>",
"    ]. These findings are accompanied by histopathologic evidence of associated tissue damage or recovery of a mold or yeast by culture of a specimen obtained from a normally sterile site, or by a radiological abnormality consistent with an infectious disease process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5219179\">",
"    <span class=\"h2\">",
"     Criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Burn Association (ABA) consensus criteria for the definition of sepsis and infection in burn patients includes",
"    <strong>",
"     at least three",
"    </strong>",
"    of the following parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature &gt;102.2&deg;F (39&deg;C) or &lt;97.7&deg;F (36.5&deg;C)",
"     </li>",
"     <li>",
"      Progressive tachycardia (eg, adults &gt;90 beats per minute; children &gt;2 standard deviations [SD] above age specific normal values [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/13\">",
"       13",
"      </a>",
"      ]) (",
"      <a class=\"graphic graphic_table graphicRef83352 \" href=\"UTD.htm?31/36/32332\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Progressive tachypnea (eg, adults &gt;30 breathes per minute; children &gt;2 SD above age specific normal values [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/13\">",
"       13",
"      </a>",
"      ]) (",
"      <a class=\"graphic graphic_table graphicRef83352 \" href=\"UTD.htm?31/36/32332\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Refractory hypotension (eg, adults: systolic blood pressure &lt;90 mmHg or a decrease &gt;40 mmHg, or mean arterial pressure &lt;70 mmHg; children &lt;2 SD below normal) (",
"      <a class=\"graphic graphic_table graphicRef83352 \" href=\"UTD.htm?31/36/32332\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Leukocytosis (eg, adult &gt;12,000 white",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      children &gt;2 SD above normal) or leukocytopenia (eg, &lt;4000 white blood",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef83352 \" href=\"UTD.htm?31/36/32332\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Thrombocytopenia that occurs three days after resuscitation (eg, adults &lt;100,000 platelets per microliter; children &lt;2 SD below age-specific normal values) (",
"      <a class=\"graphic graphic_table graphicRef66999 \" href=\"UTD.htm?32/34/33326\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperglycemia &gt;110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the absence of pre-existing diabetes mellitus",
"     </li>",
"     <li>",
"      Inability to tolerate enteral feedings for more than 24 hours based upon:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abdominal distention",
"     </li>",
"     <li>",
"      Residual volumes (two times the feeding rate in adults and &gt;150",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"      in children)",
"     </li>",
"     <li>",
"      Uncontrollable diarrhea (&gt;2500",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      for adults and &gt;400",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      for children)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the ABA definition",
"    <strong>",
"     requires",
"    </strong>",
"    that the infection be documented by one of the following evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection is confirmed on a culture (eg, wound, blood, urine),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Pathologic tissue source is identified (&gt;10",
"      <sup>",
"       5",
"      </sup>",
"      bacteria on quantitative wound tissue biopsy",
"      <strong>",
"       or",
"      </strong>",
"      microbial invasion on biopsy),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      A clinical response to antimicrobial administration is documented",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bacteremia and fungemia are reviewed as separate topics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=see_link&amp;anchor=H12#H12\">",
"     \"Blood cultures for the detection of bacteremia\", section on 'Interpreting positive cultures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112272480\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF BURN WOUND INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn wound infections are classified by the pathologic concentrations of bacteria per gram of tissue, burn wound histopathology, and clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/6,14-23\">",
"     6,14-23",
"    </a>",
"    ]. These distinct clinical characteristics of the spectrum of burn wound infections are described in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H85983534\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The classification categories include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112272488\">",
"    <span class=\"h2\">",
"     Bacterial colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial colonization is defined as &lt;10",
"    <sup>",
"     5",
"    </sup>",
"    bacteria per gram of tissue, and does not generally impair wound healing. Colonization is present when bacteria are cultured from the burn wound surface in the absence of clinical or microscopic evidence of infection or invasion of unburned tissue. These low levels of bacteria stimulate the inflammatory response, activate macrophages, and produce growth factors and cytokines that aid in wound healing. They also prevent overgrowth of nonresident bacteria. (See",
"    <a class=\"local\" href=\"#H5226891\">",
"     'Diagnostic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112272496\">",
"    <span class=\"h2\">",
"     Noninvasive bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infection occurs when bacteria are present in the burn wound and eschar at concentrations &gt;10",
"    <sup>",
"     5",
"    </sup>",
"    <span class=\"nowrap\">",
"     bacteria/gram",
"    </span>",
"    tissue. Although no invasive infection is present in unburned tissue, this bacterial burden results in impaired skin and tissue graft take, and promotes systemic infection. Quantitative cultures and burn wound histology are required for this diagnosis. Patients with bacterial counts in excess of 10",
"    <sup>",
"     5",
"    </sup>",
"    <span class=\"nowrap\">",
"     organisms/gram",
"    </span>",
"    tissue in the burn eschar should be considered at risk for developing an invasive burn wound infection (burn wound sepsis), even if the burns are excised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112272526\">",
"    <span class=\"h2\">",
"     Burn-related surgical wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn-related surgical wound infection (&gt;10",
"    <sup>",
"     5",
"    </sup>",
"    bacteria per gram of tissue) occurs in the excised burn wound as well as donor sites that have not yet reepithelialized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112272534\">",
"    <span class=\"h2\">",
"     Burn wound cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn wound cellulitis is an extension of infection into healthy, uninjured skin and soft tissue. It is characterized by erythema involving uninjured skin greater than expected based upon the burn injury itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112272542\">",
"    <span class=\"h2\">",
"     Burn wound impetigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn wound impetigo is the loss of epithelium due to an infection at a previously reepithelialized surface, such as a grafted burn, a partial-thickness burn allowed to heal by secondary intention, or a healed donor site. It is not related to inadequate excision of the burn, mechanical disruption of the graft, or hematoma formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112272550\">",
"    <span class=\"h2\">",
"     Invasive burn wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An invasive burn wound infection (&gt;10",
"    <sup>",
"     5",
"    </sup>",
"    bacteria per gram of tissue) is an infection that occurs in an unexcised deep partial-thickness or full-thickness burn wound and adjacent unburned tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192003552\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intact, healthy skin surface has bacteriostatic properties that normally limit the degree of skin colonization by pathogens and noninvasive resident microbes. Thermal destruction of the skin barrier is associated with profound alterations in host defense mechanisms and immune function. Inflammatory mediators that alter the baseline metabolic profile of the burn patient are continuously released, the baseline temperature is reset to approximately 101.3&deg;F (38.5&deg;C), and tachycardia and tachypnea persist for months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]. Subsequent defects in humoral and cell-mediated immunity are pivotal factors contributing to infectious complications in patients with severe burns [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/14,15,24,25\">",
"     14,15,24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Burned patients lose their protective primary barrier (skin) to environmental microorganisms. The burn itself consists of avascular necrotic tissue (eschar) that provides a protein-rich environment favorable to microbial colonization and proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The avascularity of the eschar impairs migration of host immune cells and restricts delivery of systemically administered antimicrobial agents, while toxic substances released by eschar tissue impair local host immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The flora of the burn wound influences the risk as well as the invasive potential of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1\">",
"     1",
"    </a>",
"    ]. The organisms causing burn wound infection appear at varying stages of postburn injury. The chronologic appearance and the characteristics of organisms in burns are included in the table (",
"    <a class=\"graphic graphic_table graphicRef83410 \" href=\"UTD.htm?4/1/4124\">",
"     table 5",
"    </a>",
"    ). The microbial population immediately after a thermal injury is sparse, and colonization includes predominantly gram-positive bacteria, such as staphylococci (S. aureus, P. aeruginosa, and S. marcescens), that are located deep within sweat glands and hair follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. Gram-negative organisms become the predominant organisms two to four days postburn injury, and within the first week, burns are colonized with gram-positive bacteria, gram-negative bacteria, fungi derived from the patient&rsquo;s normal gastrointestinal and upper respiratory flora, and flora from the hospital environment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1,17,18,26\">",
"     1,17,18,26",
"    </a>",
"    ]. Gram-negative pathogens, with antimicrobial resistance traits, dominate the course of burn wound infection after the fifth day following a severe burn [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/18,27\">",
"     18,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A noninvasive bacterial infection in the burn and eschar results in impaired healing and promotes systemic infection (sepsis). In the case of a burn-associated immune deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed or inadequate treatment approaches, microbial invasion of viable tissue occurs, which represents the hallmark of an invasive burn wound infection (burn wound sepsis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungi (eg, Candida",
"    <em>",
"    </em>",
"    species) and multiresistant organisms (eg, Methicillin-resistant Staphylococcus aureus [MRSA], vancomycin-resistant Enterococcus [VRE], Acenitobacter) appear later, and typically occur after use of broad-spectrum antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a prolonged hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=see_link\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8098153\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common pathogens for burn infections and sepsis include methicillin-sensitive Staphylococcus aureus (MSSA), MRSA, and Pseudomonas aeruginosa. The predominant gram-positive organisms found in burn wound infections remain Staphylococcus aureus, followed by Enterococcus species. Pseudomonas aeruginosa remains the most frequent gram-negative microorganism isolated from burn wounds, followed by E. coli.",
"   </p>",
"   <p>",
"    Candida species are the most common fungi isolated from burn wounds and the fourth most common cause of burn wound infections overall [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/2\">",
"     2",
"    </a>",
"    ], and HSV-1 remains the most common viral organism in burn wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/18\">",
"     18",
"    </a>",
"    ]. The characteristic physical findings of these common organisms are described in the table (",
"    <a class=\"graphic graphic_table graphicRef83411 \" href=\"UTD.htm?8/62/9195\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5224860\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of developing an invasive wound infection at the burn",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin graft donor site following a severe burn is determined by several clinical factors, including patient age (ie, very young and very old), impaired immune status, extensiveness of burn injury (&gt;20 percent total body surface area), and the depth of the initial burn (deeper than superficial). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification of burns\", section on 'Burn depth'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microbial factors, such as type (eg, gram-negative bacteria) and number of organisms (&gt;10",
"    <sup>",
"     5",
"    </sup>",
"    organisms per gram of tissue), enzyme and toxin production, and microbial motility also increase the risk of an invasive wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1,17,18,26\">",
"     1,17,18,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192005881\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8098085\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid change in symptoms (eg, fever, pain) and wound appearance (eg, purulent drainage, erythema, tenderness) are indications of an invasive infection and burn wound sepsis. Clinical symptoms and signs of an infection will be absent when a burn wound is colonized with a pathogen or resident bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5219186\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with invasive burn wound infections (burn wound sepsis) may report fever symptoms and changes (eg, color, pain, swelling, odor) in wound appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192006787\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive burn wound infections are most often recognized based upon systemic symptoms, the gross appearance of the burn",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin graft donor site, and alterations in clinical measurements (eg, vital signs, abdominal distention, residual tube feedings). Systemic signs of sepsis include tachypnea, hypotension, oliguria, unexplained hyperglycemia, and mental status change (eg, confusion). The clinical criteria for an invasive infection are described by the American Burn Association (ABA) diagnostic parameters. (See",
"    <a class=\"local\" href=\"#H5219179\">",
"     'Criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832170\">",
"    <span class=\"h4\">",
"     Clinical measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical findings are associated with invasive burn wound infections and sepsis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature &gt;39&deg;C or &lt;36.5&deg;C",
"     </li>",
"     <li>",
"      Progressive tachycardia (eg, adults &gt;90 beats per minute; children &gt;2 SD above age-specific normal values) (",
"      <a class=\"graphic graphic_table graphicRef83352 \" href=\"UTD.htm?31/36/32332\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Progressive tachypnea (eg, adults &gt;30 breaths per minute; children &gt;2 SD above age-specific normal values) (",
"      <a class=\"graphic graphic_table graphicRef83352 \" href=\"UTD.htm?31/36/32332\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Refractory hypotension (eg, adults: systolic blood pressure &lt;90 mmHg or a decrease &gt;40 mmHg, or mean arterial pressure &lt;70 mmHg; children &lt;2 SD below normal)",
"     </li>",
"     <li>",
"      Inability to tolerate enteral feedings for more than 24 hours based upon:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abdominal distention",
"     </li>",
"     <li>",
"      Residual volumes (two times the feeding rate in adults and &gt;150",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"      in children)",
"     </li>",
"     <li>",
"      Uncontrollable diarrhea (&gt;2500",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      for adults and &gt;400",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      for children)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832194\">",
"    <span class=\"h4\">",
"     Burn wound appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local signs of an invasive burn wound infection include conversion of an area of partial-thickness burn to full-thickness burn",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of an infection that has developed at a previously reepithelialized surface, such as a grafted burn, partial-thickness burn allowed to heal by secondary intention, or a healed donor site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification of burns\", section on 'Burn depth'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Invasive burn wound infection characteristics include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1,17,18,26,28,29\">",
"     1,17,18,26,28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid change in appearance of the wound",
"     </li>",
"     <li>",
"      Appearance of focal, multifocal, or generalized dark brown, black, or violaceous discoloration of the wound",
"     </li>",
"     <li>",
"      Separation or discoloration of the eschar",
"     </li>",
"     <li>",
"      Hemorrhagic discoloration of subeschar tissue",
"     </li>",
"     <li>",
"      Presence of green pigment (pyocyanin) in subcutaneous fat (ie, Pseudomonas infection)",
"     </li>",
"     <li>",
"      Erythema, edema, pain, warmth of surrounding skin",
"     </li>",
"     <li>",
"      Edema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      violaceous discoloration at the margin of the burn and unburned skin",
"     </li>",
"     <li>",
"      Presence of initially erythematous and later black necrotic nodular lesions (ecthyma gangrenosa) in adjacent unburned skin",
"     </li>",
"     <li>",
"      Exophthalmos may be the first sign of mucormycosis in midface burns (retrobulbar space involvement)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local signs characteristic of burn wound infections caused by fungi include unexpectedly rapid separation of the eschar, presumably due to fat liquefaction, and rapid spread of subcutaneous edema with central ischemic necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/29\">",
"     29",
"    </a>",
"    ]. Vesicular lesions that appear in healing or healed second-degree burns and the presence of crusted serrated margins of partial-thickness burns of the face, particularly those involving the nasolabial area, are characteristic of burn wound infections caused by herpes simplex virus type 1 (HSV-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192006802\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192006810\">",
"    <span class=\"h3\">",
"     Burn wound culture findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an infected burn wound and eschar, bacteria are present at concentrations &gt;10",
"    <sup>",
"     5",
"    </sup>",
"    bacteria per gram of tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In an invasive burn wound infection, bacteria are identified at concentrations &gt;10",
"    <sup>",
"     5",
"    </sup>",
"    <span class=\"nowrap\">",
"     bacteria/gram",
"    </span>",
"    tissue in adjacent unburned tissue. Fungal infections are confirmed by the presence of hyphae by culture of microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192006818\">",
"    <span class=\"h3\">",
"     Histopathologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even when cultures grow &gt;10",
"    <sup>",
"     5",
"    </sup>",
"    organisms per gram of tissue, microorganisms are found in only 50 percent of histopathological examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/16\">",
"     16",
"    </a>",
"    ]. The use of quantitative microbiological assessments facilitates burn wound surveillance and establishes a presumptive diagnosis of invasive infection when bacterial colonization is &gt;10",
"    <sup>",
"     5",
"    </sup>",
"    organisms per gram of tissue.",
"   </p>",
"   <p>",
"    The presence of microorganisms in adjacent viable unburned tissue confirms the diagnosis of an invasive burn wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1,16,18,20,21\">",
"     1,16,18,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other histopathologic findings in unburned tissue include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of hemorrhage",
"     </li>",
"     <li>",
"      Small-vessel thrombosis",
"     </li>",
"     <li>",
"      Ischemic necrosis",
"     </li>",
"     <li>",
"      Marked inflammatory changes",
"     </li>",
"     <li>",
"      Dense bacterial growth in the subeschar space (a site of microbial proliferation prior to invasion)",
"     </li>",
"     <li>",
"      Intracellular viral inclusions typical for herpes viral infections (HSV-1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832058\">",
"    <span class=\"h3\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following alterations in blood tests can be found in patients with invasive burn wound infection:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832449\">",
"    <span class=\"h4\">",
"     Glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasting serum blood glucose levels &gt;110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in the absence of pre-existing diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\", section on 'Glucose metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832457\">",
"    <span class=\"h4\">",
"     White blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis (&gt;12,000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    adults; &gt;2 SD above the normal level for children) (",
"    <a class=\"graphic graphic_table graphicRef83352 \" href=\"UTD.htm?31/36/32332\">",
"     table 2",
"    </a>",
"    ) or leukocytopenia &lt;4000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832465\">",
"    <span class=\"h4\">",
"     Platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet",
"    count",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    (adults); &lt;2 SD below the normal level for children (",
"    <a class=\"graphic graphic_table graphicRef66999 \" href=\"UTD.htm?32/34/33326\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8098105\">",
"    <span class=\"h3\">",
"     Blood or urine cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of a pathogen in blood or urine cultures in the absence of another identifiable source of infection is consistent with a burn sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192003559\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative burn wound cultures and tissue histopathology are required to confirm the presence of a burn wound infection. (See",
"    <a class=\"local\" href=\"#H112272480\">",
"     'Classification of burn wound infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of an invasive burn wound infection and sepsis is made based upon the following parameters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestations (eg, fever or hypothermia, pain, progressive tachypnea, rapid change in burn wound appearance, leukocytosis or leukocytopenia, thrombocytopenia) (see",
"      <a class=\"local\" href=\"#H5219179\">",
"       'Criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8098085\">",
"       'Clinical manifestations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Fulfillment of one of the three",
"      <strong>",
"       required",
"      </strong>",
"      American Burn Association (ABA) consensus criteria (see",
"      <a class=\"local\" href=\"#H5219179\">",
"       'Criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pathologic infection is confirmed on a culture (eg, wound, blood, urine ),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Pathologic tissue source is identified (ie, &gt;10",
"      <sup>",
"       5",
"      </sup>",
"      bacteria on quantitative wound tissue biopsy",
"      <strong>",
"       or",
"      </strong>",
"      microbial invasion on biopsy),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Improvement in the clinical setting is attributed to antimicrobial administration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85983534\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of an invasive burn wound infection (burn wound sepsis) includes the spectrum of burn wound infections, toxic epidermal necrolysis, and hypermetabolic response to burn. (See",
"    <a class=\"local\" href=\"#H112272480\">",
"     'Classification of burn wound infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Burn wound colonization",
"      </strong>",
"      is defined as &lt;10",
"      <sup>",
"       5",
"      </sup>",
"      <span class=\"nowrap\">",
"       bacteria/gram",
"      </span>",
"      tissue cultured from the burn wound surface, in the absence of clinical or microscopic evidence of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/18\">",
"       18",
"      </a>",
"      ]. Clinical signs and symptoms of an infection are absent in colonization.",
"     </li>",
"     <li>",
"      <strong>",
"       Noninvasive bacterial infection",
"      </strong>",
"      is present in burns when the bacterial count is &gt;10",
"      <sup>",
"       5",
"      </sup>",
"      <span class=\"nowrap\">",
"       bacteria/gram",
"      </span>",
"      tissue without an invasive component identified by tissue histopathology (microbial invasion into unburned tissue). An acute infection manifests as erythema, pain, purulent exudate, and edema surrounding the wound without the systemic findings described for an invasive burn infection. (See",
"      <a class=\"local\" href=\"#H5219179\">",
"       'Criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Burn-related surgical wound infection",
"      </strong>",
"      (&gt;10",
"      <sup>",
"       5",
"      </sup>",
"      <span class=\"nowrap\">",
"       bacteria/gram",
"      </span>",
"      tissue) occurs in the excised burn as well as donor sites that have not yet reepithelialized and is characterized by purulent exudate, loss of synthetic or biologic covering, wound hyperemia, and erythema of surrounding uninjured skin. Microorganisms have not invaded into normal adjacent tissue based upon the tissue histopathology and systemic symptoms and signs are not present. (See",
"      <a class=\"local\" href=\"#H5219179\">",
"       'Criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Burn wound cellulitis",
"      </strong>",
"      (&gt;10",
"      <sup>",
"       5",
"      </sup>",
"      <span class=\"nowrap\">",
"       bacteria/gram",
"      </span>",
"      tissue) is characterized by erythema involving unburned skin greater than expected for the burn injury itself, and no invasive component is identified by tissue histopathology. The presence of one or more clinical findings are identified:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Localized pain and tenderness",
"     </li>",
"     <li>",
"      Localized swelling",
"     </li>",
"     <li>",
"      Localized skin warmth",
"     </li>",
"     <li>",
"      Progression of swelling and erythema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Burn wound impetigo",
"      </strong>",
"      appears as necrosis or infection in a previously reepithelialized grafted",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      donor site. No invasive component is identified by tissue histopathology and systemic symptoms and signs are not present.",
"     </li>",
"     <li>",
"      <strong>",
"       Toxic epidermal necrolysis",
"      </strong>",
"      (TEN), or Lyell's syndrome, is characterized by widely distributed cutaneous erythematous macules or patches,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diffuse cutaneous erythema (",
"      <a class=\"graphic graphic_picture graphicRef68458 graphicRef82150 graphicRef59418 graphicRef66134 \" href=\"UTD.htm?33/20/34122\">",
"       picture 1A-D",
"      </a>",
"      ). TEN begins with a prodrome of fever and malaise, temperatures 102.2&deg;F (39&deg;C). In the early stages, skin pain may be prominent and out of proportion to clinical findings. The skin lesions progress to full-thickness epidermal necrosis. The ultimate appearance of the skin is similar to that of extensive thermal injury. Mucous membranes are involved in nearly all cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link&amp;anchor=H3#H3\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\", section on 'Toxic epidermal necrolysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypermetabolic response to thermal burn",
"      </strong>",
"      is characterized by a hyperdynamic circulatory response with massive protein and lipid catabolism, total body protein loss, muscle wasting, peripheral insulin resistance, increased energy expenditure, increased body temperature, increased infection risks (local and systemic), and stimulated synthesis of acute phase proteins. The metabolic rate increases proportionally to the increase in burn size. For example, adults with a 25 percent total body surface area (TBSA) burn injury develop a metabolic rate between 118 to 210 percent of the predicted basal metabolic rate; children with burn injuries greater than 40 percent TBSA develop a metabolic rate of 180 percent of the predicted basal metabolic rate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"       \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5226891\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an invasive burn wound infection is clinically suspected, qualitative cultures can identify the presence of flora, but quantitative cultures and histopathology are required to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5225795\">",
"    <span class=\"h2\">",
"     Qualitative wound cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn wound surface swab cultures provide a qualitative assessment of the local flora. The spectrum of microorganisms causing infections in burn patients varies with time and location; and swab cultures assist in the surveillance of the bacterial flora colonizing burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathogens are detected by the following techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteria are detected using a Gram stain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34791?source=see_link\">",
"       \"Approach to Gram stain and culture results in the microbiology laboratory\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fungi (eg, Candida, Aspergillus-like morphology, mucor-like morphology) are detected by a standard morphological appearance on various stains (periodic acid-Schiff [PAS] and Gomori",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"       methenamine",
"      </a>",
"      silver [GMS]) (",
"      <a class=\"graphic graphic_table graphicRef83411 \" href=\"UTD.htm?8/62/9195\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link\">",
"       \"Diagnosis of invasive aspergillosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link&amp;anchor=H14#H14\">",
"       \"Mucormycosis (zygomycosis)\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viruses, such as Herpes simplex virus, can be identified as inclusions on light or electron microscopy, or isolated from tissue biopsy specimens or lesion scrapings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H835866\">",
"    <span class=\"h2\">",
"     Quantitative tissue cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative tissue cultures must be obtained to identify the pathogen. While swab surface wound cultures can identify the predominant burn wound flora, quantitative microbiological tissue cultures establish the presumptive diagnosis of an infection when bacterial counts are more than 10",
"    <sup>",
"     5",
"    </sup>",
"    organisms per gram of tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The tissue biopsy samples should be obtained from several areas of the burn and should be approximately 1 to 2 cm in length, 1.5 cm deep, and extend into the subcutaneous tissue, or weigh approximately 0.5 gram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H836546\">",
"    <span class=\"h2\">",
"     Tissue histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue histopathology allows for quantification and evaluation of infection depth and involvement of unburned skin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/18\">",
"     18",
"    </a>",
"    ]. The presence of microorganisms in unburned tissue identified by histopathologic examination confirms the diagnosis of an invasive burn wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1,16,20,21\">",
"     1,16,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122386746\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early excision and skin grafting (days one to five) reduces the presence of potentially necrotic and infected tissue, and thereby reduces the risk of invasive and noninvasive burn wound infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Early excision of necrotic tissue and closure of the burn wound has been one of the single greatest advancements in the treatment of patients with severe thermal injuries, and a mainstay of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H22158166#H22158166\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Early excision and skin grafting'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link&amp;anchor=H16#H16\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\", section on 'Early wound closure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of invasive burn wound infections (burn wound sepsis) includes topical and systemic therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122386766\">",
"    <span class=\"h2\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local management of infected burn wounds includes cleansing, debridement, topical antimicrobial agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    , combination antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ), and dressings (eg, compresses, biosynthetics, biologics). The use of topical agents is reserved for noninvasive wound infections; once the infections invade adjacent normal tissue, then the treatment becomes aggressive excision. Topical management is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4452349\">",
"    <span class=\"h2\">",
"     Excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive fungal infections should be treated with wide excision of the involved tissue. Phycomycotic infections may be surrounded by a rim of edematous tissue, which also must be excised. These excised wounds benefit from topical and systemic therapy. The excised wounds need to be inspected again within 24 to 48 hours, and debrided again if necrotic tissue is present, or if the wound is clean, covered with allograft if no infected tissue remains and the wound appears viable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/29,33-35\">",
"     29,33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122386840\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy with antibiotics and antifungals is reserved for patients demonstrating sepsis or septic shock because of the risk of super-infection with resistant microorganisms. (See",
"    <a class=\"local\" href=\"#H5219179\">",
"     'Criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Empiric antimicrobial therapy to treat fever is strongly discouraged since burn patients frequently have increased body temperature secondary to the systemic inflammatory response to burn injury. Antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antifungals are unnecessary for burn wound colonization and noninvasive burn infections.",
"    <span class=\"nowrap\">",
"     Antibiotic/antifungal",
"    </span>",
"    therapy is directed towards the specific microbial isolated from wound, blood,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/58/21417/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific antimicrobial therapies are reviewed elsewhere and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H17#H17\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Antimicrobial regimen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H9034264#H9034264\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Initial antimicrobial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"       \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=see_link\">",
"       \"Treatment of Staphylococcus aureus bacteremia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H230580859#H230580859\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Antifungal therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of candidemia in children\", section on 'Antifungal agents and dosing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85983200\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals who sustain a severe burn (&gt;20 percent total body surface area) are at a high risk of developing an invasive burn wound infection, also referred to as burn wound sepsis, which often leads to multi-organ dysfunction and death. (See",
"      <a class=\"local\" href=\"#H192003545\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A noninvasive bacterial infection in the burn wound and eschar is defined as &gt;10",
"      <sup>",
"       5",
"      </sup>",
"      bacteria per gram of tissue. An invasive burn wound infection, also called burn wound sepsis, is defined as the presence of microorganisms in adjacent unburned tissue. (See",
"      <a class=\"local\" href=\"#H192006955\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American Burn Association (ABA) consensus criteria for the definition of sepsis and infection in burn patients",
"      <strong>",
"       includes at least three clinical features",
"      </strong>",
"      for the diagnosis of burn infection and sepsis, including fever or hypothermia, tachypnea, tachycardia, refractory hypotension, leukocytosis or leukopenia, hyperglycemia, thrombocytopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inability to tolerate tube feedings for 24 hours.",
"     </li>",
"     <li>",
"      ABA consensus criteria",
"      <strong>",
"       requires",
"      </strong>",
"      that the infection be documented by one of the following: infection is confirmed on a culture,",
"      <strong>",
"       or",
"      </strong>",
"      the pathologic tissue source is identified (&gt;10",
"      <sup>",
"       5",
"      </sup>",
"      bacteria on quantitative wound tissue biopsy",
"      <strong>",
"       or",
"      </strong>",
"      microbial invasion on biopsy),",
"      <strong>",
"       or",
"      </strong>",
"      a clinical response to antimicrobial administration is documented. (See",
"      <a class=\"local\" href=\"#H5219179\">",
"       'Criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ABA consensus criteria Quantitative tissue cultures establish the presumptive diagnosis of an infection when bacterial counts are more than 10",
"      <sup>",
"       5",
"      </sup>",
"      organisms per gram of tissue. (See",
"      <a class=\"local\" href=\"#H192006818\">",
"       'Histopathologic findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H835866\">",
"       'Quantitative tissue cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue histopathology allows for quantification and evaluation of infection depth and involvement of unburned skin. (See",
"      <a class=\"local\" href=\"#H192006818\">",
"       'Histopathologic findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H836546\">",
"       'Tissue histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infected burn wounds are managed by local cleansing, debridement, topical antimicrobial agents, and dressings. (See",
"      <a class=\"local\" href=\"#H122386746\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"       \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We reserve the use of systemic antimicrobials for patients that exhibit signs and symptoms of burn wound sepsis. (See",
"      <a class=\"local\" href=\"#H122386746\">",
"       'Treatment'",
"      </a>",
"      above.) Systemic therapy should be specifically directed towards the microbial organism isolated from culture.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/1\">",
"      Pruitt BA Jr, McManus AT, Kim SH, Goodwin CW. Burn wound infections: current status. World J Surg 1998; 22:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/2\">",
"      Branski LK, Al-Mousawi A, Rivero H, et al. Emerging infections in burns. Surg Infect (Larchmt) 2009; 10:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/3\">",
"      Fitzwater J, Purdue GF, Hunt JL, O'Keefe GE. The risk factors and time course of sepsis and organ dysfunction after burn trauma. J Trauma 2003; 54:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/4\">",
"      Hospital and prehospital resources for optimal care of patients with burn injury: guidelines for development and operation of burn centers. American Burn Association. J Burn Care Rehabil 1990; 11:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/5\">",
"      Richards C, Emori TG, Edwards J, et al. Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control 2001; 29:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/6\">",
"      Greenhalgh DG, Saffle JR, Holmes JH 4th, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007; 28:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/7\">",
"      D'Avignon LC, Saffle JR, Chung KK, Cancio LC. Prevention and management of infections associated with burns in the combat casualty. J Trauma 2008; 64:S277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/8\">",
"      Miranda BH, Ali SN, Jeffery SL, Thomas SS. Two stage study of wound microorganisms affecting burns and plastic surgery inpatients. J Burn Care Res 2008; 29:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/9\">",
"      Wibbenmeyer LA, Kealey GP, Latenser BA, et al. Emergence of the USA300 strain of methicillin-resistant Staphylococcus aureus in a burn-trauma unit. J Burn Care Res 2008; 29:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/10\">",
"      De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/11\">",
"      Jeschke MG, Gauglitz GG, Kulp GA, et al. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One 2011; 6:e21245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/12\">",
"      Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg 2008; 248:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/13\">",
"      Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/14\">",
"      Hansbrough JF, Field TO Jr, Gadd MA, Soderberg C. Immune response modulation after burn injury: T cells and antibodies. J Burn Care Rehabil 1987; 8:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/15\">",
"      Heideman M, Bengtsson A. The immunologic response to thermal injury. World J Surg 1992; 16:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/16\">",
"      Barret JP, Herndon DN. Effects of burn wound excision on bacterial colonization and invasion. Plast Reconstr Surg 2003; 111:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/17\">",
"      Erol S, Altoparlak U, Akcay MN, et al. Changes of microbial flora and wound colonization in burned patients. Burns 2004; 30:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/18\">",
"      Church D, Elsayed S, Reid O, et al. Burn wound infections. Clin Microbiol Rev 2006; 19:403.",
"     </a>",
"    </li>",
"    <li>",
"     Heggers JP, Robson MC(Eds.). Quantitative Bacteriology: Its Role in the Armamentarium of the Surgeon, 1st Ed. Boca Raton, Fla.: CRC Press, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/20\">",
"      McManus AT, Kim SH, McManus WF, et al. Comparison of quantitative microbiology and histopathology in divided burn-wound biopsy specimens. Arch Surg 1987; 122:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/21\">",
"      Pruitt BA Jr, McManus AT. The changing epidemiology of infection in burn patients. World J Surg 1992; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/22\">",
"      Mayhall CG. The epidemiology of burn wound infections: then and now. Clin Infect Dis 2003; 37:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/23\">",
"      Peck MD, Weber J, McManus A, et al. Surveillance of burn wound infections: a proposal for definitions. J Burn Care Rehabil 1998; 19:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/24\">",
"      Alexander JW. Mechanism of immunologic suppression in burn injury. J Trauma 1990; 30:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/25\">",
"      Griswold JA. White blood cell response to burn injury. Semin Nephrol 1993; 13:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/26\">",
"      Altoparlak U, Erol S, Akcay MN, et al. The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 2004; 30:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/27\">",
"      Azzopardi EA, Azzopardi SM, Boyce DE, Dickson WA. Emerging gram-negative infections in burn wounds. J Burn Care Res 2011; 32:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/28\">",
"      Pruitt BA Jr, Lindberg RB, McManus WF, Mason AD Jr. Current approach to prevention and treatment of Pseudomonas aeruginosa infections in burned patients. Rev Infect Dis 1983; 5 Suppl 5:S889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/29\">",
"      Pruitt BA Jr. The diagnosis and treatment of infection in the burn patient. Burns Incl Therm Inj 1984; 11:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/30\">",
"      Foley FD, Greenawald KA, Nash G, Pruitt BA Jr. Herpesvirus infection in burned patients. N Engl J Med 1970; 282:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/31\">",
"      Guggenheim M, Zbinden R, Handschin AE, et al. Changes in bacterial isolates from burn wounds and their antibiograms: a 20-year study (1986-2005). Burns 2009; 35:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/32\">",
"      Rezaei E, Safari H, Naderinasab M, Aliakbarian H. Common pathogens in burn wound and changes in their drug sensitivity. Burns 2011; 37:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/33\">",
"      Nash G, Foley FD, Goodwin MN Jr, et al. Fungal burn wound infection. JAMA 1971; 215:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/58/21417/abstract/34\">",
"      Spebar MJ, Walters MJ, Pruitt BA Jr. Improved survival with aggressive surgical management of noncandidal fungal infections of the burn wound. J Trauma 1982; 22:867.",
"     </a>",
"    </li>",
"    <li>",
"     Cancio LC, Howard PA, McManus AT. Burn wound infections. In: Surgical Treatment: Evidence-Based and Problem Oriented, Holzheimer RG, Mannick JA.  (Eds), Zuckschwerdt, 2001.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14985 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21417=[""].join("\n");
var outline_f20_58_21417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H85983200\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192003545\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192006955\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5219179\">",
"      Criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112272480\">",
"      CLASSIFICATION OF BURN WOUND INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112272488\">",
"      Bacterial colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112272496\">",
"      Noninvasive bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112272526\">",
"      Burn-related surgical wound infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112272534\">",
"      Burn wound cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112272542\">",
"      Burn wound impetigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112272550\">",
"      Invasive burn wound infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192003552\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8098153\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5224860\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192005881\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8098085\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5219186\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192006787\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832170\">",
"      Clinical measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832194\">",
"      Burn wound appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192006802\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192006810\">",
"      - Burn wound culture findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192006818\">",
"      - Histopathologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H832058\">",
"      - Blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832449\">",
"      Glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832457\">",
"      White blood count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H832465\">",
"      Platelet count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8098105\">",
"      - Blood or urine cultures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192003559\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85983534\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5226891\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5225795\">",
"      Qualitative wound cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H835866\">",
"      Quantitative tissue cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H836546\">",
"      Tissue histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H122386746\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122386766\">",
"      Topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4452349\">",
"      Excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122386840\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85983200\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14985|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/1/39953\" title=\"picture 1A\">",
"      Toxic epidermal necrolysis - back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/18/35106\" title=\"picture 1B\">",
"      Toxic epidermal necrolysis - bullae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/27/13747\" title=\"picture 1C\">",
"      Toxic epidermal necrolysis - abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/63/18419\" title=\"picture 1D\">",
"      Toxic epidermal necrolysis I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/13/2268\" title=\"table 1\">",
"      American Burn Association grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/36/32332\" title=\"table 2\">",
"      Physiologic parameters based on pediatric age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 3\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/34/33326\" title=\"table 4\">",
"      Normal range for coagulation tests in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/1/4124\" title=\"table 5\">",
"      Chronologic appearance and characteristics of organisms in burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/62/9195\" title=\"table 6\">",
"      Appearance of infected burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34791?source=related_link\">",
"      Approach to Gram stain and culture results in the microbiology laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=related_link\">",
"      Blood cultures for the detection of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=related_link\">",
"      Principles of burn reconstruction: Overview of surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=related_link\">",
"      Treatment of candidemia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_58_21418="Timing of intraaortic balloon pump inflation and deflation";
var content_f20_58_21418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 640px\">",
"   <div class=\"ttl\">",
"    Timing of intraaortic balloon pump inflation and deflation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 620px; height: 571px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The timing of balloon inflation is adjusted until it occurs late in diastole, uncovering the dicrotic notch. Subsequently, inflation timing is moved earlier in the cardiac cycle until the dicrotic notch on the central aortic tracing just disappears (beat #4). The augmented pressure will rise as inflation timing is moved earlier.",
"    <br/>",
"    (B) Deflation knob is moved toward the right (later in the cardiac cycle) until the end diastolic dip is 10 to 15 mmHg below the patient's unassisted diastolic pressure. This will produce a maximal lowering of the patient's unassisted systolic pressure.",
"    <br/>",
"    (C) The balloon console is triggering on an atrial pacing artifact. This is corrected by changing the console to a mode that will discriminate between a pacing spike and an R wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aroesty J. Percutaneous intraaortic balloon insertion. In: Cardiac Catheterization and Angiography, 3rd ed, Grossman W (Ed), Lea &amp; Febiger, Philadelphia 1986. Copyright &copy; 1986 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21418=[""].join("\n");
var outline_f20_58_21418=null;
var title_f20_58_21419="Muscles of larynx";
var content_f20_58_21419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Muscles of the larynx",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Muscle",
"      </td>",
"      <td class=\"subtitle1\">",
"       Innervation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Action",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cricothyrioid",
"      </td>",
"      <td>",
"       External branch of superior laryngeal",
"      </td>",
"      <td>",
"       Elongates, thins, and lowers the vocal fold",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Posterior cricoarytenoid",
"      </td>",
"      <td>",
"       Recurrent laryngeal",
"      </td>",
"      <td>",
"       Sole abductor of the larynx; elevates, elongates, and thins the vocal fold",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lateral cricoarytenoid",
"      </td>",
"      <td>",
"       Recurrent laryngeal",
"      </td>",
"      <td>",
"       Elongates, thins, and adducts the vocal fold",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Interarytenoid",
"      </td>",
"      <td>",
"       Recurrent laryngeal and branches of the superior laryngeal",
"      </td>",
"      <td>",
"       Adducts the vocal fold",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aryepiglottic",
"      </td>",
"      <td>",
"       Recurrent laryngeal",
"      </td>",
"      <td>",
"       Adducts the vocal fold and aryepiglottic fold",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thyroarytenoid",
"      </td>",
"      <td>",
"       Recurrent laryngeal",
"      </td>",
"      <td>",
"       Adducts the vocal fold",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vocalis (part of the thyroarytenoid)",
"      </td>",
"      <td>",
"       Recurrent laryngeal",
"      </td>",
"      <td>",
"       Adducts and thickens the vocal fold",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21419=[""].join("\n");
var outline_f20_58_21419=null;
var title_f20_58_21420="Urinary clues to inborn errors of metabolism";
var content_f20_58_21420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Urinary clues to inborn errors of metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential",
"disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Urine color",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Black (upon standing/oxidation)",
"       </td>",
"       <td>",
"        Homogentisic aciduria (alkaptonuria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blue",
"       </td>",
"       <td>",
"        Tryptophan malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pink",
"       </td>",
"       <td>",
"        Disorders with hematuria, kidney stone formation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Port wine (upon standing/oxidation)",
"       </td>",
"       <td>",
"        Porphyrias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yellow-orange",
"       </td>",
"       <td>",
"        Disorders with increased uric acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Urine",
"odor*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acrid, sweaty feet",
"       </td>",
"       <td>",
"        Glutaric acidemia II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cabbage",
"       </td>",
"       <td>",
"        Tyrosinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fishy",
"       </td>",
"       <td>",
"        Trimethlylaminuria, dimethylglycinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maple syrup, curry",
"       </td>",
"       <td>",
"        Maple syrup urine disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mousy",
"       </td>",
"       <td>",
"        Phenylketonuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sweaty feet",
"       </td>",
"       <td>",
"        Isovaleric acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sweet",
"       </td>",
"       <td>",
"        Beta-ketothiolase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Swimming pool",
"       </td>",
"       <td>",
"        Hawkinsinuria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Only in acute phases or depending on food intake.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Wappner, RS, Hainline, BE. Inborn errors of metabolism. In: Oski's Pediatrics. Principles and Practice, 3rd ed, McMillan, JA, DeAngelis, CD, Feigin, RD, Warshaw, JB (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, 1999. p. 1823 and Saudubray, JM, Chappentier, C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver, CR, Beaudet, AL, Sly, WS, Valle, D (Eds), McGraw-Hill, New York, 2001. p. 1327.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21420=[""].join("\n");
var outline_f20_58_21420=null;
var title_f20_58_21421="Rapid overview acute decompensated heart failure";
var content_f20_58_21421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview: Acute decompensated heart failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Differential diagnosis: Pulmonary embolism, acute asthma, pneumonia, noncardiogenic pulmonary edema (eg, ARDS), pericardial tamponade or constriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms and signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute dyspnea, orthopnea, tachypnea, tachycardia, and hypertension are common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension reflects severe disease and arrest may be imminent; assess for inadequate peripheral or end-organ perfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accessory muscles are often used to breathe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse pulmonary crackles are common; wheezing (cardiac asthma) may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S3 is a specific sign but may not be audible; elevated jugular venous pressure and/or peripheral edema may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain ECG: Look for evidence of ischemia, infarction, arrhythmia (eg, atrial fibrillation), and left ventricular hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain portable chest x-ray: Look for signs of pulmonary edema, cardiomegaly, alternative diagnoses (eg, pneumonia); Normal radiograph does not rule out ADHF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain: Blood counts; cardiac troponin; electrolytes (Na+, K+, Cl-, HCO3-); BUN and creatinine; arterial blood gas; BNP or NT-proBNP if diagnosis is uncertain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform bedside echocardiography if available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor oxygen saturation, vital signs, and cardiac rhythm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide supplemental oxygen, place two IV catheters, and position patient upright",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide noninvasive positive pressure ventilation (NIPPV), unless immediate intubation is needed or NIPPV is otherwise contraindicated; have airway management equipment readily available; etomidate is a good induction agent for rapid sequence intubation in ADHF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Search for cause of ADHF (including: acute coronary syndrome, hypertension, arrhythmia, acute aortic or mitral regurgitation, aortic dissection, sepsis, renal failure, or anemia) and treat appropriately",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patients with ADHF and atrial fibrillation (AF) often require medication (eg, esmolol) to slow their heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Direct current cardioversion is indicated for patients with new onset AF and hemodynamic instability or refractory symptoms despite rate control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obtain immediate cardiac surgery consultation for acute aortic or mitral regurgitation or ascending aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        For patients with adequate end-organ perfusion (eg, normal or elevated blood pressure) and signs of ADHF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give an IV vasodilator (nitroglycerin or nitroprusside); titrate rapidly to effect (eg, start nitroglycerin at 20 mcg/minute and increase dose by 40 to 50 mcg every&nbsp;three to&nbsp;five minutes as needed); nitrates are contraindicated after use of PDE-5 inhibitors (eg, sildenafil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give an IV loop diuretic (eg, furosemide 40 mg IV; bumetanide 1 mg IV); higher doses are needed for patients taking diuretics chronically (give an IV dose at least equal to the chronic oral dose) and patients with renal dysfunction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        For patients with known systolic heart failure (eg, documented low ejection fraction) presenting with signs of severe ADHF and hypotension or signs of shock:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give an IV inotrope (eg, dobutamine or milrinone) and mechanical support (eg, intraaortic balloon counter pulsation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        For patients with known diastolic heart failure (ie, preserved systolic function) presenting with signs of severe ADHF and hypotension or signs of shock:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give an IV vasopressor (eg, phenylephrine); do not give an inotrope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Consider possibility of acute mitral or aortic regurgitation, or aortic dissection, and need for emergent surgical intervention. Obtain immediate echocardiography if available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        For patients whose cardiac status is unknown but present with signs of severe ADHF (ie, pulmonary edema) and hypotension or signs of shock:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give an IV inotrope (eg, dobutamine or milrinone), with or without an IV vasopressor (eg, norepinephrine) and mechanical support (eg, intraaortic balloon counter pulsation)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21421=[""].join("\n");
var outline_f20_58_21421=null;
var title_f20_58_21422="Herbal remedies avoid";
var content_f20_58_21422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Specific herbal remedies to discourage and avoid during chemotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Herb",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concurrent chemotherapy/condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suspected effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Black cohosh",
"       </td>",
"       <td>",
"        Avoid with cisplatin; discourage in patients with estrogen receptor-positive breast cancer and endometrial cancer (potential stimulation of tumor growth)",
"       </td>",
"       <td>",
"        <p>",
"         CYP 2D6 inhibition (modest)",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         Potential estrogenic effects",
"        </p>",
"        Additive hepatotoxicity (inconclusive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinacea",
"       </td>",
"       <td>",
"        Avoid with camptothecins, cyclophosphamide, EGFR-TK inhibitors, epipodophyllotoxins, taxanes, and vinca alkaloids",
"       </td>",
"       <td>",
"        <p>",
"         CYP 1A2 inhibition",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         CYP 2C9 induction (modest)",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        CYP 3A4 induction and inhibition (inconclusive)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Garlic (concentrated garlic supplements and garlic oil)",
"       </td>",
"       <td>",
"        Avoid with dacarbazine and other substrates of CYP 2E1; caution with other concurrent chemotherapy",
"       </td>",
"       <td>",
"        <p>",
"         CYP 2E1 inhibition",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         CYP 2C19, 3A4 and P-gp inhibition (inconclusive)",
"        </p>",
"        Inhibition of platelet function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td style=\"height: 163px;\">",
"        Ginkgo biloba",
"       </td>",
"       <td>",
"        Caution with camptothecins, cyclophosphamide, EGFR-TK inhibitors, epipodophyllotoxins, taxanes, and vinca alkaloids; discourage with alkylating agents, antitumor antibiotics, and platinum analogues",
"       </td>",
"       <td>",
"        <p>",
"         CYP 3A4 inhibition",
"         <sup>",
"          [1]",
"         </sup>",
"         (modest)",
"        </p>",
"        <p>",
"         CYP 2C19 induction",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         CYP 1A2, 2C9, 2D6 and P-gp inhibition (inconclusive)",
"        </p>",
"        <p>",
"         Hypersensitivity reactions",
"        </p>",
"        <p>",
"         Free-radical scavenging",
"        </p>",
"        <p>",
"         Inhibition of platelet function",
"        </p>",
"        <p>",
"         Elevated serotonin effects",
"        </p>",
"        <p>",
"         Decreased seizure threshold",
"        </p>",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Seed, fruit, and nut parts have been associated more frequently with neurotoxicity, hypersensitivity, and drug interactions than extracts of leafy parts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ginseng (American, Panax or Siberian)",
"       </td>",
"       <td>",
"        Caution with camptothecins, cyclophosphamide, EGFR-TK inhibitors, epipodophyllotoxins, taxanes, imatinib",
"        <sup>",
"         2",
"        </sup>",
"        , and vinca alkaloids; discourage in patients with estrogen receptor-positive breast cancer and endometrial cancer (potential stimulation of tumor growth)",
"       </td>",
"       <td>",
"        <p>",
"         CYP 2C9, 2D6, and 3A4 inhibition (inconclusive or minor effects)",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         Estrogenic effects",
"        </p>",
"        <p>",
"         Additive hepatotoxicity potential",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Green tea",
"       </td>",
"       <td>",
"        Concentrated green tea extracts and large quantities of green tea should be avoided with bortezomib",
"       </td>",
"       <td>",
"        <p>",
"         Inactivation of boronic acid-based proteosome inhibition",
"         <sup>",
"          [3,4]",
"         </sup>",
"        </p>",
"        <p>",
"         Potential for additive hepatotoxicity",
"        </p>",
"        Effects of caffeine content (diuresis, insomnia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grape seed",
"       </td>",
"       <td>",
"        Caution with camptothecins, cyclophosphamide, EGFR-TK inhibitors, epipodophyllotoxins, taxanes, and vinca alkaloids (CYP3A4 induction), and with alkylating agents, antitumor antibiotics, and platinum analogues (free-radical scavenging)",
"       </td>",
"       <td>",
"        <p>",
"         CYP 1A2, 3A4 induction",
"        </p>",
"        Free-radical scavenging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grapefruit and grapefruit juice (large quantities)",
"       </td>",
"       <td>",
"        Avoid with substrates of CYP 3A4 and/or P-glycoprotein transporters including: crizotinib, etoposide, everolimus, ifosfamide, lapatinib, nilotinib, pazopanib, ruxolitinib, taxanes, topotecan, and vinca alkaloids, including liposomal vincristine",
"       </td>",
"       <td>",
"        <p>",
"         Inhibition of CYP 3A4 and P-glycoprotein (P-gp) transporters (established)",
"        </p>",
"        <p>",
"         Inhibition of CYP 1A2, 2C19, 2C9 (possible)",
"        </p>",
"        Organic anion transporting polypeptide (OATP) inhibition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kava kava",
"       </td>",
"       <td>",
"        Avoid in all patients with pre-existing liver disease, with evidence of hepatic injury (herb-induced hepatotoxicity), and/or in combination with potentially hepatotoxic chemotherapy; caution with camptothecins, cyclophosphamide, EGFR-TK inhibitors, epipodophyllotoxins, taxanes, and vinca alkaloids",
"       </td>",
"       <td>",
"        <p>",
"         CYP 2E1 inhibition",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         CYP 3A4 induction (inconclusive)",
"        </p>",
"        <p>",
"         P-glycoprotein inhibition (inconclusive)",
"        </p>",
"        Additive hepatotoxicity potential (established)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milk thistle",
"       </td>",
"       <td>",
"        Avoid with tamoxifen",
"        <sup>",
"         5",
"        </sup>",
"       </td>",
"       <td>",
"        CYP1A2, 2C9, 2D6, 2E1, and 3A4 (inconclusive)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        St. John's wort",
"       </td>",
"       <td>",
"        <strong>",
"         Avoid with all concurrent chemotherapy",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         CYP2B6, CYP2C9, CYP2C19, CYP2E1, CYP3A4, and P-glycoprotein induction",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         Elevated serotonin effects",
"        </p>",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Microsomal induction effects of St. Johns wort may persist for two or more weeks following its discontinuation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soy",
"       </td>",
"       <td>",
"        Avoid with tamoxifen (potential antagonism of tumor growth inhibition), and during any antitumor therapy in patients with estrogen receptor-positive breast cancer or endometrial cancer (potential stimulation of tumor growth)",
"       </td>",
"       <td>",
"        <p>",
"         CYP 2C9 inhibition (minimal)",
"        </p>",
"        Estrogenic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valerian",
"       </td>",
"       <td>",
"        Caution with tamoxifen, cyclophosphamide, and teniposide",
"       </td>",
"       <td>",
"        CYP 2C9, 2C19, and 3A4 inhibition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        No specific interactions expected when herbs are used in typical doses*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Bilberry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Cranberry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Evening primrose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Ginger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Saw palmetto",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Interaction effects due to herbal remedies are highly variable based upon quantity, potency, and parts of herbs ingested and, in general, due to a lack of standardization of available preparations. Refer to UpToDate topic on Overview of herbal medicine and dietary supplements. This list is not comprehensive. Additional specific interactions may be determined using the drug interactions program included in UpToDate. This program can be accessed from the UpToDate new search page or through the individual drug monographs section on Drug Interactions.",
"    <div class=\"footnotes\">",
"     EGFR-TK: epidermal growth factor receptor tyrosine-kinase.",
"     <br>",
"      * Non chemotherapy-associated precautions may apply. For example, excessive doses of ginger may be associated with dysfunction of platelet aggregation, hypoglycemic, and hypotensive effects.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Additional references:",
"     <br>",
"      <ol>",
"       <li>",
"        Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet 2012; 51:77.",
"       </li>",
"       <li>",
"        Bilgi N, Bell K, Ananthakrishnan AN, et al. Imatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity. Ann Pharmacother 2010; 44:926.",
"       </li>",
"       <li>",
"        Golden EB, Lam PY, Kardosh A, et al. Green Tea Polyphenols Block the Anticancer Effects of Bortezomib and Other Boronic Acid-Based Proteasome Inhibitors. Blood 2009; 113:5927.",
"       </li>",
"       <li>",
"        Liu FT, Agrawal SG, Movasaghi Z, et al. Dietary Flavonoids Inhibit the Anticancer Effects of the Proteasome Inhibitor Bortezomib. Blood 2008; 112:3835.",
"       </li>",
"       <li>",
"        Kim CS, Choi SJ, Park CY, et al. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res 2010; 30:79.",
"       </li>",
"      </ol>",
"      <br>",
"       Adapted and expanded from: Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22:2489.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21422=[""].join("\n");
var outline_f20_58_21422=null;
var title_f20_58_21423="US appendicitis in pregnancy2";
var content_f20_58_21423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sonogram of appendicitis in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the right lower quadrant in a woman with appendicitis at 21 weeks of gestation. Note the fluid-filled appendix with appendicoliths (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_58_21423=[""].join("\n");
var outline_f20_58_21423=null;
